MIXTURE OF HMOS AND B. INFANTIS

A composition of Bifidobacterium longum subspecies infantis with specific human milk oligosaccharides addresses the challenge of viral infections and respiratory conditions by promoting a healthy microbiome, leading to rapid disease resolution and long-term immune benefits.

BR112025025068A2Pending Publication Date: 2026-11-10SOCIETE DES PRODUITS NESTLE SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025025068
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-16
Filing Date
2024-05-15
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

There is a need for effective compositions to prevent and treat viral infections, particularly in the respiratory tract, and to reduce the risk of developing respiratory conditions such as asthma, due to the challenges in maintaining a healthy gastrointestinal microbiome, especially in formula-fed infants, and the limited means to prevent or treat viral infections.

Method used

A composition comprising Bifidobacterium longum subspecies infantis in combination with a mixture of human milk oligosaccharides, including 2'-fucosyl-lactose, difucosyllactose, lacto-N-tetraose, 6'-sialyllactose, 3'-sialyllactose, and lacto-N-neotetraose, is administered to support a healthy microbiome, providing protection against virus-induced bronchiolitis and promoting sustained immune benefits.

Benefits of technology

The symbiotic intervention leads to rapid resolution of virus-induced lung inflammation, reduces the risk of respiratory conditions, and provides long-term immune benefits, potentially preventing asthma and chronic obstructive pulmonary disease.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a composition for use in preventing and / or treating a viral infection in a subject, wherein the composition comprises Bifidobacterium longum subsp. infantis and a HMO mixture consisting of 2'-fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), 3'-sialyllactose (3SL), and lacto-N-neotetraose (LNnT), and optionally 3-fucosyllactose (3FL). The invention also provides the composition for use in preventing and / or reducing the risk of allergen sensitisation, preventing and / or reducing the risk of developing a respiratory condition in a subject, and / or preventing and / or reducing the risk of developing asthma in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 76 MIXTURE OF HMOS AND B. INFANTIS FIELD OF THE INVENTION

[001] The present invention relates to a composition comprising Bifidobacterium longum subspecies infantis and a mixture of human milk oligosaccharides (HMOs) consisting of 2'-fucosyl-lactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyllactose (3SL), and lacto-N-neotetraose (LNnT) and optionally 3-fucosyllactose (3FL). The invention also relates to applications of the composition in human health, for example, to i) prevent and / or treat a viral infection in an individual, ii) prevent and / or reduce the risk of sensitization to allergens, iii) prevent and / or reduce the risk of developing a respiratory condition in an individual and / or iv) prevent and / or reduce the risk of developing asthma. BACKGROUND OF THE INVENTION

[002] A viral infection occurs when the virus multiplies within the host cells and thus utilizes the host's resources to promote its own multiplication. Viral infections can also interfere with the normal functioning of the host and can lead to more serious infection-related disorders, including long-term changes in the immune system (such as inflammatory responses) and subsequent allergic or inflammatory diseases later in life.

[003] Viral respiratory infections, such as respiratory syncytial virus (RSV), affect nearly 90% of children by the age of two (Karpinnen et al, Clin Microbiol Infect, 2016;22; 208.e1 to e6) and often lead to bronchiolitis, a bronchial inflammatory reaction in infants and young children (Pickles et al, J Pathol, 2015;235;266 to 276). In particular, severe RSV-induced bronchiolitis is a major cause of morbidity and Petition 870250104625, dated 11 / 14 / 2025, p. 11 / 117 2 / 76 infant mortality worldwide (Nair et al, Lancet, 2010; 375; 9725; 2545-1555). Respiratory viruses primarily infect the airway epithelium. Higher viral loads have been associated with increased severity of bronchiolitis, and conversely, rapid reduction of viral load in infants has been associated with faster resolution of the disease (Pickles et al, J Pathol, 2015; 235; 266-276). It is well documented that infected and necrotic epithelial cells contribute to airway obstruction and inflammation during RSV infection (Pickles et al, J Pathol, 2015;235; 266-276), and thus, epithelial cell shedding is a characteristic of viral bronchiolitis and is associated with disease severity (Johnson et al, Mod Pathol, 2007;20;108-119).Plasmacytoid dendritic cells (pDCs) are known to be protective against pathology during RSV infection, and adaptive immune responses, including CD4+ and CD8+ T cells, are important in viral clearance from the respiratory tract (Openshaw et al, Annu Rev Immunol, 2017;35;501-532).

[004] If the immune defense response to such viral respiratory infections is dysregulated, inflammatory granulocytes, such as neutrophils, along with CD4+ and CD8+ T cell responses, can also lead to immunopathology following respiratory viral infection (Newton et al, Semin Immunopathol, 2016;38;471-482). Furthermore, such uncontrolled inflammatory responses can also lead to pathological remodeling of airway smooth muscle, a hallmark of asthma reported to begin early in life (O'Reilly et al, Jaci, 2013;131;1024-1032), as well as playing a central role in the pathogenesis of chronic obstructive pulmonary disease (COPD; Yan F et al, J. Transl Med, 2018;16;262-270). Thus, severe viral airway infections early in life represent an independent risk factor for Petition 870250104625, dated 11 / 14 / 2025, page 12 / 117 3 / 76 subsequent development of respiratory diseases, such as allergic airway diseases (e.g., asthma; Feldman et al, Am J Respir Crit Care Med, 2015;191;34-44) and chronic obstructive pulmonary disease (Savran O et al. Int J Chron Obstruct Pulmon Dis. 2018; 13: 683-693) later in life.

[005] Breastfeeding is a recognized factor that reduces the severity of respiratory viral infection in infants, either directly through milk bioactives (e.g., human milk oligosaccharides) or indirectly through immunological benefits mediated by microbiomes.

[006] Human milk oligosaccharides (HMOs) have been the subject of much interest in recent years due to their functions in numerous biological processes that occur in the human body. Mammalian milk contains at least 130 of these complex oligosaccharides (Urashima et al., Milk Oligosaccharides, Nova Biomedical Books, New York, 2011, ISBN: 978-1-61122-831-1).

[007] Infancy, especially in the first weeks, 3 months, months, or 12 months of life, is a critical period for the establishment of a balanced gut microbiota. It is known that modulation of the gastrointestinal tract microbiota during infancy and early childhood can have a significant influence on the future health status of the body. For example, the gut microbiome can influence the development of a strong immune system in later life stages, as well as normal growth, and even the development of obesity in later life stages. It is also known that the mode of delivery can affect the initial gastrointestinal tract microbiota of infants: babies born by cesarean section (C-section) have been shown to have a different gut microbiota compared to babies born vaginally.

[008] Bifidobacterium longum subspecies infantis (B. infantis) Petition 870250104625, dated 11 / 14 / 2025, page 13 / 117 4 / 76 has been shown to be predominant in the gastrointestinal microbiota of breastfed infants and to benefit the host by accelerating the maturation of the immune response, balancing the immune system to suppress inflammation, improving intestinal barrier function, and increasing the production of short-chain fatty acids (SCFAs). Reduced abundance of Bifidobacterium species in infants and young children has been correlated with chronic diseases, including asthma and obesity, as well as decreased vaccine response. Researchers have postulated that the loss of Bifidobacterium species in the infant gut in populations from developed countries is linked to an increased incidence of allergic and autoimmune diseases.

[009] It is known that probiotics, in particular, of the genus Lactobacillus and Bifidobacterium support protection against respiratory tract infections. The role of probiotics in viral respiratory tract infections was reviewed by Lehtoranta and colleagues (Lehtoranta et al, Eur J Clin Microbiol Infect Dis, 2014;33; 1289 a 1302).

[0010] Increasing the abundance of Bifidobacterium species, or specifically B. infantis, in the gastrointestinal tract's microbial ecosystem through exogenous administration can be difficult to achieve, especially in formula-fed infants. Administering a probiotic through nutritional compositions, such as infant formulas, typically aims to promote its grafting into the gastrointestinal tract's microbiome so that the desired benefits associated with said probiotic can be obtained. The great diversity of the microbial community in the gastrointestinal tract makes probiotic grafting challenging.

[0011] Due to the loss of Bifidobacterium species in the baby's gastrointestinal tract and low breastfeeding rates, there is a Petition 870250104625, dated 11 / 14 / 2025, p. 14 / 117 5 / 76 need to provide babies with HMOs and HMO-using bacteria, such as infant B. longum subspecies, to support a healthy microbiome for long-term health.

[0012] Furthermore, there are limited means to prevent or treat viral infections. There are a limited number of effective antiviral drugs, for example, drugs used to treat HIV and influenza, and the main method for controlling viral disease is vaccination, which is intended to prevent outbreaks by building immunity against a virus or a family of viruses.

[0013] Thus, there is a need for a composition to prevent and / or treat viral infections and, more specifically, to prevent or treat viral infections of the respiratory tract. SUMMARY OF THE INVENTION

[0014] The present inventors have surprisingly discovered that symbiotic intervention (B. infantis in combination with a mixture of human milk oligosaccharides) early in life provides protection against virus-induced bronchiolitis and promotes a sustained immune benefit into adulthood (as assessed by reduced susceptibility to pollution-induced allergic airway inflammation). Specifically, the present inventors have shown that symbiotic interventions resulted in rapid resolution of virus-induced lung inflammation and proper lung tissue remodeling after virus clearance.

[0015] These findings support the use of synbiotics in providing protection and treatment of viral infections, particularly viral bronchiolitis, early in life and demonstrate functional benefits of synbiotics in mounting effective antiviral immune responses associated with faster disease resolution. Given that viral respiratory tract infections early in life Petition 870250104625, dated 11 / 14 / 2025, page 15 / 117 6 / 76 represent an important independent risk factor for subsequent asthma, recurrent wheezing, and chronic obstructive pulmonary disease; dietary supplementation with synbiotics may also prevent long-term complications associated with early-life viral respiratory tract infections.

[0016] Consequently, in a first aspect, the present invention provides a composition for use in the prevention and / or treatment of a viral infection in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMO oligosaccharides consisting of 2'-fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), 3'-sialyllactose (3SL), and lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyllactose (3FL).

[0017] In another aspect, the invention provides a composition for use i) in the prevention and / or reduction of the risk of sensitization to allergens in the respiratory tract and / or ii) in the prevention and / or reduction of the risk of developing a respiratory condition in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), 3'-sialyllactose (3SL), and lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyllactose (3FL), wherein the respiratory condition is a chronic inflammatory disease of the respiratory tract or an allergic disease of the respiratory tract.

[0018] In some embodiments, the composition is intended for use in the prevention and / or reduction of the risk of sensitization to allergens in an individual's respiratory tract.

[0019] In some embodiments, the composition is intended for use in the prevention and / or reduction of the risk of developing a respiratory condition in an individual. Petition 870250104625, dated 11 / 14 / 2025, p. 16 / 117 7 / 76

[0020] In another aspect, the invention provides a composition for use in preventing and / or reducing the risk of developing asthma in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-Ntetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL), and lacto-Nneotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL).

[0021] In some forms, the HMO mixture consists of 2'-fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), 3'-sialyllactose (3SL) and lacto-N-neotetraose (LNnT).

[0022] In some forms, the HMO mixture consists of 2'-fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), 3'-sialyllactose (3SL), 3-fucosyllactose (3FL) and lacto-N-neotetraose (LNnT).

[0023] In some embodiments, Bifidobacterium longum subspecies infantis is Bifidobacterium longum subspecies infantis LMG 11588.

[0024] In some embodiments, Bifidobacterium longum subspecies infantis is a strain with an Average Nucleotide Identity (ANI) of at least 99.9% with Bifidobacterium longum subspecies infantis LMG 11588.

[0025] In some forms, the HMO mixture consists essentially of: I. 34% by weight to 85% by weight of 2FL, preferably 40% by weight to 71% by weight; ii. 10% by weight to 40% by weight of LNT, preferably 12% by weight to 26% by weight; iii. 4% to 14% by weight of DFL, preferably 5% to 10% by weight; Petition 870250104625, dated 11 / 14 / 2025, page 17 / 117 8 / 76 iv. 9% by weight to 31% by weight of 6SL and 3SL combined, preferably 10% by weight to 28% by weight; and v. 6% by weight to 30% by weight of LNnT, preferably 7% by weight to 22% by weight.

[0026] In some forms, the HMO mixture consists essentially of: i. 20% by weight to 60% by weight of 2FL, preferably 22% by weight to 55% by weight; ii. 4% by weight to 30% by weight of LNT, preferably 6% by weight to 20% by weight; iii. 1% by weight to 12% by weight of DFL, preferably 2% by weight to 8% by weight; iv. 7% by weight to 23% by weight of 6SL and 3SL combined, preferably 8% by weight to 22% by weight; v. 10% by weight to 50% by weight of 3FL, preferably 13% by weight to 46% by weight; and vi. 3% by weight to 25% by weight of LNnT, preferably 5% by weight to 20% by weight.

[0027] In some forms, the composition is in the form of a nutritional composition.

[0028] In some embodiments, the nutritional composition is selected from an infant formula, an infant starter formula, a transition or follow-on formula, an infant food, an infant cereal composition, a growing-up milk, a fortifier, such as a human milk fortifier, or a supplement.

[0029] In some modalities, the individual is a baby, a toddler, or a child. Appropriately, the individual is a baby. Appropriately, the individual is a toddler. Appropriately, the individual is a child. Petition 870250104625, dated 11 / 14 / 2025, page 18 / 117 9 / 76

[0030] In a further aspect, the invention provides the use of a composition according to the invention for the manufacture of a medicament to prevent and / or treat a viral infection in an individual.

[0031] In a further aspect, the invention provides the use of a composition according to the invention for the manufacture of a medicament for i) preventing and / or reducing the risk of sensitization to allergens in the respiratory tract and / or ii) preventing and / or reducing the risk of developing a respiratory condition in an individual, wherein the respiratory condition is a chronic inflammatory disease of the respiratory tract or an allergic disease of the respiratory tract.

[0032] In a further aspect, the invention provides the use of a composition according to the invention for the manufacture of a medicament to prevent and / or reduce the risk of developing asthma in an individual.

[0033] In a further aspect, the invention provides a method of preventing and / or treating a viral infection in an individual, wherein the method comprises administering to the individual a composition in accordance with the invention.

[0034] In a further aspect, the invention provides a method of i) preventing and / or reducing the risk of sensitization to allergens in the respiratory tract and / or ii) preventing and / or reducing the risk of developing a respiratory condition in an individual, wherein the method comprises administering to the individual a composition according to the invention, wherein the respiratory condition is a chronic inflammatory disease of the respiratory tract or an allergic disease of the respiratory tract.

[0035] In another aspect, the invention provides a method for preventing and / or reducing the risk of developing asthma in an individual, the method comprising administering to the individual Petition 870250104625, dated 11 / 14 / 2025, page 19 / 117 10 / 76 a composition according to the invention.

[0036] In another aspect, the invention provides a composition comprising Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3-sialyllactose (3SL) and lacto-N-neotetraose (LNnT).

[0037] In another aspect, the invention provides a composition comprising Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyllactose (3SL), 3-fucosyl-lactose (3FL) and lacto-N-neotetraose (LNnT). BRIEF DESCRIPTION OF THE FIGURES

[0038] Figure 1: Schematic drawing of the model of viral airway infection in early life and allergic airway inflammation intensified by pollution.

[0039] Figure 2: Early life nutritional intervention with a symbiotic (B. infantis + 6HMOs) reduces virus-induced lung pathology.

[0040] Figures 3 and 4: Early life nutritional intervention with a symbiotic (B. infantis + 6HMOs) promotes sustained immunological benefits into adulthood.

[0041] Figure 5: Early life nutritional intervention with a synbiotic (B. infantis + 5HMOs) promotes antiviral immune responses at the peak of infection and reduces virus-induced lung inflammation.

[0042] Figure 6: Synergy between the 7-HMOs in combination with B. infantis in the establishment of B. breve within fecal fermentation cultures. DETAILED DESCRIPTION OF THE INVENTION Definitions Petition 870250104625, dated 11 / 14 / 2025, page 20 / 117 11 / 76

[0043] As used herein, the following terms have the meanings below.

[0044] The term individual refers to a baby, toddler, child, a small-for-gestational-age (SGA) baby, or a preterm baby.

[0045] The term baby means a child up to 12 months old.

[0046] The expression toddler means a child between one and three years old, also called a 1 to 3 year old.

[0047] The term child means a child aged between three and twelve years. Preferably, the term child means a child aged between three and six years.

[0048] A preterm or premature individual means a baby or young child who was not born at term. Generally, the term refers to a baby or young child who was born before 36 weeks of gestation.

[0049] The expression small for gestational age or SGA stands for a baby or toddler who is smaller than normal for their gestational age at birth, most commonly defined as a weight below the 10th percentile for gestational age. In some modalities, SGA may be associated with intrauterine growth restriction (IUGR), which refers to a condition in which a fetus is unable to reach its potential size.

[0050] The term low birth weight should be understood as any body weight below 2,500g at birth.

[0051] The term nutritional composition means a composition that nourishes an individual. This nutritional composition is usually taken orally or intravenously. It can Petition 870250104625, dated 11 / 14 / 2025, p. 21 / 117 12 / 76 include a source of lipids or fat, a source of carbohydrate and / or a source of protein. In a specific embodiment, the nutritional composition is a ready-to-drink composition, such as a ready-to-drink formula.

[0052] In a specific embodiment, the nutritional composition of the present invention is a synthetic nutritional composition. The term synthetic nutritional composition means a mixture obtained by a chemical and / or biological means, which may be chemically identical to the naturally occurring mixture in mammalian milk (i.e., the synthetic nutritional composition is not breast milk).

[0053] The term infant formula, as used herein, refers to a food product intended for specific nutritional use by infants during the first months of life and which, by itself, satisfies the nutritional needs of that category of person (Article 2(c) of Commission Directive 91 / 321 / EEC 2006 / 141 / EC of 22 December 2006 on infant formulas and follow-on formulas). It also refers to nutritional compositions intended for infants as defined in the Codex Alimentarius (Codex STAN 72-1981) and Infant Specialities (including Food for Special Medical Purposes).

[0054] The term infant formula encompasses both infant starter formula and follow-up or transition formula.

[0055] A follow-on or transitional formula is given from the 6th month onwards and includes growing-up milk. It constitutes the main liquid element in the progressively diversified diet of this category of person.

[0056] The term growing-up milk (or LC) refers to a milk-based drink, usually with added vitamins and minerals. Petition 870250104625, dated 11 / 14 / 2025, page 22 / 117 13 / 76 added, which is intended for toddlers or children.

[0057] The term baby food means a food product intended for specific nutritional use by babies or young children during the first years of life.

[0058] The term cereal composition for babies means a food product intended for specific nutritional use by babies or young children during the first years of life.

[0059] The term fortifier refers to liquid or solid nutritional compositions suitable for mixing with breast milk or infant formula.

[0060] The term weaning period means the period during which breast milk is replaced by another food in the diet of a baby or young child.

[0061] The term breast milk should be understood as the milk produced by the mother's breasts or the mother's colostrum.

[0062] An oligosaccharide is a saccharide polymer that contains a small number (typically three to ten) of simple sugars (monosaccharides).

[0063] The term HMO or HMOs refers to human milk oligosaccharide(s). These carbohydrates are resistant to enzymatic hydrolysis by digestive enzymes (e.g., pancreatic or brush border), indicating that they may have essential functions not directly related to their caloric value. It has been especially illustrated that they play a vital role in the early development of infants and children, such as the maturation of the immune system. Many different types of HMOs are found in human milk. Each individual oligosaccharide is based on a combination of glucose, galactose, sialic acid (N-acetylneuraminic acid), fucose, and / or N-acetylglucosamine with many and varied linkages between them, thus constituting the Petition 870250104625, dated 11 / 14 / 2025, page 23 / 117 14 / 76 A huge number of different oligosaccharides are found in human milk – more than 130 such structures have been identified so far. Almost all of them have a lactose moiety at their reducing end while sialic acid and / or fucose (when present) occupy terminal positions at the non-reducing ends. HMOs can be acidic (e.g., oligosaccharide containing charged sialic acid) or neutral (e.g., fucosylated oligosaccharide). Some examples of HMOs are fucosylated oligosaccharides, N-acetylated oligosaccharides, and / or sialylated oligosaccharides.

[0064] A fucosylated oligosaccharide is an oligosaccharide that has a fucose residue. It has a neutral nature. Some examples are LNFP-I (lacto-N-fucopentaose I), 2'-FL (2' fucosyllactose), 3-FL (3-fucosyl-lactose).

[0065] The expressions fucosylated oligosaccharides comprising an alpha-1,2-fucosyl-epitope and 2-fucosylated oligosaccharides encompass fucosylated oligosaccharides with a certain homology of form, since they contain an alpha-1,2'-fucosyl-epitope, therefore, a certain homology of function can be expected.

[0066] The term N-acetylated oligosaccharides encompasses both N-acetyl-lactosamine and oligosaccharides containing N-acetyl-lactosamine. They are neutral oligosaccharides that have an N-acetyl-lactosamine residue. Suitable examples are LNT (lactoN-tetraose), para-lacto-N-neo-hexaose (para-LNnH), LNnT (lacto-N-neotetraose), or any combination thereof. Other examples are lacto-N-hexaose, lacto-N-neo-hexaose, para-lacto-N-hexaose, paralacto-N-neo-hexaose, lacto-N-octaose, lacto-N-neo-octaose, iso-lactoN-octaose, para-lacto-N-octaose, and lacto-N-decaose.

[0067] A sialylated oligosaccharide is a charged sialic acid-containing oligosaccharide, that is, an oligosaccharide having a sialic acid residue. It has an acidic nature. Some Petition 870250104625, dated 11 / 14 / 2025, p. 24 / 117 15 / 76 examples are 3'-SL (3'-sialyl-lactose) and 6'SL (6'-sialyl-lactose). The terms sialylated oligosaccharide and sialyl-lactose (SL) can be used interchangeably. The sialyl-lactose trisaccharide consists of lactose at the reducing end and a sialic acid residue at the non-reducing end via an alpha-2,3 linkage or an alpha-2,6 linkage, resulting in 3'-SL and 6'-SL, respectively.

[0068] An HMO precursor is a key compound involved in the production of HMOs, such as sialic acid and / or fucose.

[0069] The term GOS, as used herein, means galactooligosaccharide. Galacto-oligosaccharides (GOS), as used herein, typically consist of galactose moieties β-linked with galactose or glucose at the reducing end. Such GOS contain galactose moieties linked to β-(1^2), β-(1^3), β-(1^4) or β-(1^6) and may have a degree of polymerization (DP) of 3 to 8 galactose units. The term GOS is therefore preferably referred to as oligosaccharide(s) comprising at least three galactose units, more preferably as oligosaccharide(s) comprising at least four galactose units, preferably having a degree of polymerization (DP) of 3 to 8 galactose units.

[0070] The nutritional composition of the present invention may be in solid form (e.g., powder) or in liquid form. The amount of the various ingredients (e.g., oligosaccharides) may be expressed in g / 100 g of the composition on a dry weight basis when in solid form, e.g., a powder, or as a concentration in g / l of the composition when referring to a liquid form (the latter also covers the liquid composition that may be obtained from a powder after reconstitution in a liquid such as milk, water, for example, a reconstituted infant formula or follow-on / follow-up formula or growing-up milk). Petition 870250104625, dated 11 / 14 / 2025, page 25 / 117 16 / 76 or infant cereal product or any other formulation intended for infant nutrition).

[0071] The terms exclusively breastfed infants / young children, exclusively breastfed infants or young children, exclusively breastfed infants or young children, and breastfed infants / young children may be used interchangeably. They refer to infants or young children who are fed a large majority (i.e., at least 90%, or at least 95%, or at least 99%) or all (100%) of their nutrients and / or energy from human breast milk.

[0072] The term conventional nutritional composition refers to standard synthetic nutritional compositions, such as infant formulas, follow-on milks or growing-up milks already found on the market.

[0073] The terms microbial, microflora and microbiota can be used interchangeably.

[0074] The terms microbiota in the gastrointestinal tract, microbiota of the gastrointestinal tract, microbiota of the gastrointestinal tract and intestinal microbiota can be used interchangeably.

[0075] The terms "prevent" or "prevention" refer to avoiding the occurrence of a physical state, condition, or its consequences and / or decreasing its incidence (i.e., reducing its frequency). Prevention also encompasses delaying or preventing the onset of symptoms of a disease, disorder, or condition. Prevention can be absolute (so that no disease occurs) or it can be effective only in some individuals or for a limited period of time.

[0076] With the expressions treat or treatment, it is understood Petition 870250104625, dated 11 / 14 / 2025, page 26 / 117 17 / 76 a decrease in the duration and / or severity of a physical state, condition or its consequences (for example, a decrease or elimination of the symptoms of the condition). Treatment also includes reducing, alleviating or eliminating one or more symptoms associated with the disease, disorder or condition being treated and / or slowing, reducing or blocking the progression of the disease, disorder or condition being treated.

[0077] The prevention and / or treatment of a physical state, a condition or its consequences may occur during treatment (i.e., during administration of the composition of the present invention, immediately after the start of administration or some time later, for example, a few days or weeks after the start). But it may also encompass prevention and / or treatment later in life. The term later in life encompasses the effect after the end of the intervention or treatment. The later-life effect may be from 1 week to several months, or even years, for example, from 2 to 4 weeks, from 2 to 6 weeks, from 2 to 8 weeks, from 1 to 6 months or from 2 to 12 months. Appropriately, the later-life effect may be from 12 months to 12 years, as from 2 years to 10 years, or from 4 years to 5 years, after the end of the intervention or treatment.Appropriately, the effect later in life lasts until the individual is at least 5 years old, at least 10 years old, at least 20 years old, or at least 30 years old.

[0078] The term prebiotic means non-digestible carbohydrates that beneficially affect the host by selectively stimulating the growth and / or activity of healthy bacteria, such as bifidobacteria in the colon of humans (Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 1995;125:1401-12).

[0079] The term probiotic means cell preparations Petition 870250104625, dated 11 / 14 / 2025, p. 27 / 117 18 / 76 microbial or microbial cell components with a beneficial effect on the health or well-being of the host. (Salminen S, Ouwehand A. Benno Y. et al. Probiotics: how should they be defined? Trends Food Sci. Technol. 1999:10 107 a 10). Microbial cells are usually bacteria or yeasts.

[0080] The term symbiotic may refer to a component containing probiotics and prebiotics or a live microbe and a substrate that is selectively utilized by the co-administered live microbe (see, for example, Swanson, KS, et al., 2020. Nature Reviews Gastroenterology & Hepatology, 17(11), pp. 687-701).

[0081] The term ufc should be understood as colony-forming unit.

[0082] All percentages are percentages by weight, except where otherwise specified.

[0083] All weights expressed in g per 100 g of composition are dry weight, unless otherwise indicated.

[0084] The term SCFA stands for short-chain fatty acid(s).

[0085] The expression increased SCFA production means that the amount of systemic and / or colonic SCFA is greater in an individual fed the nutritional composition according to the present invention compared to a standard. SCFA production can be measured by techniques known to those skilled in the art, such as gas-liquid chromatography.

[0086] In the present context, the term gastrointestinal tract includes the mouth, pharynx, esophagus, stomach, small intestine, large intestine, rectum, and anus. The term intestine includes the small intestine, large intestine, and rectum.

[0087] In the present context, the term respiratory tract refers to the passage formed by the nose, nasal cavity, pharynx, larynx, trachea, bronchi and lungs through which the Petition 870250104625, dated 11 / 14 / 2025, page 28 / 117 19 / 76 air passes through during breathing.

[0088] Average nucleotide identity (ANI) is a measure of nucleotide-level genomic similarity between the coding regions of two genomes. Average nucleotide identity can be assessed as described here: Yoon SH, Ha SM, Lim J, Kwon S, Chun J. A large-scale evaluation of algorithms to calculate average nucleotide identity. Antonie Van Leeuwenhoek. October 2017;110(10):1281-1286. In the present embodiment, the Bifidobacterium longum subspecies infantis LMG 11588 strain (also known as ATCC 17930) represents the reference genome to which a microbial genome is compared. An example of a microorganism genome that has at least 99.9% ANI with B. longum subspecies infantis LMG 11588 can be found at PATRIC (https: / / www.patricbrc.org), genome ID 1678.111. In one embodiment of the present invention, the Bifidobacterium longum subspecies infantis strain does not harbor potentially transferable antibiotic resistances.

[0089] The ANI of genes shared between two strains is known to be a robust means of comparing the genetic relationship between strains. Strains with ANI values ​​of at least about 96% can be considered to belong to the same species (Konstantinidis and Tiedje, 2005, Proc Natl Acad Sci USA, 102(7):2567-2572; and Goris et al., 2007, Int Syst Evol Microbiol. 57(Pt 1):81-91), while ANI values ​​of at least about 99% indicate that the bacterial genomes belong to the same strain. The ANI between two bacterial genomes is calculated from pairwise comparisons of all sequences shared between any two strains and can be determined, for example, using any of a number of publicly available ANI tools, including, but not limited to, OrthoANI with usearch (Yoon et al., 2017, Antonie van Petition 870250104625, dated 11 / 14 / 2025, p. 29 / 117 20 / 76 Leeuwenhoek 110:1281 to 1286); ANI calculator, JSpecies (Richter and Rossello-Mora, 2009, Proc Natl Acad Sci USA 106: 19126 to 19131); and JSpeciesWS (Richter et al., 2016, Bioinformatics 32: 929 to 931). Other methods for determining the ANI of two genomes are known in the art (Konstantinidis, KT and Tiedje, 2005, JM, Proc. Natl. Acad. Sci. USA, 102: 2567-2572; and Varghese et al., 2015, Nucleic Acids Research, 43(14):6761 to 6771).

[0090] Furthermore, in the context of the invention, the terms "comprises" and "comprises" do not exclude other possible elements. The composition of the present invention, including the many embodiments described herein, may comprise, consist of, or essentially consist of the essential elements and limitations of the invention described herein, in addition to any additional or optional ingredients, components, or limitations described herein, or otherwise dependent on needs.

[0091] Any reference to prior art documents in this descriptive report should not be considered as an admission that such prior art is widely known or that it forms part of the common and general knowledge in the field of the art.

[0092] The invention will now be described in more detail. It is noted that the various aspects, features, examples and embodiments described in this application may be compatible and / or combined with each other in any combination thereof. Therapeutic use Viral infection

[0093] Viral respiratory infections, such as respiratory syncytial virus (RSV), affect nearly 90% of children by the age of two (Karpinnen et al, Clin Microbiol Infect, 2016;22;208.e1 to e6). Such viral respiratory infections in infants and young children often lead to bronchiolitis, an inflammatory reaction of the bronchi. Petition 870250104625, dated 11 / 14 / 2025, p. 30 / 117 21 / 76 in infants and young children (Pickles et al, J Pathol, 2015;235;266-276). Severe RSV-induced bronchiolitis is a leading cause of morbidity and mortality in infants worldwide (Nair et al, Lancet, 2010; 375; 9725; 2545-1555).

[0094] Using a Pneumonia Virus model In mice infected with human RSV (Pneumovirus of Mice), the present inventors surprisingly discovered that symbiotic intervention (B. infantis in combination with a mixture of human milk oligosaccharides) early in life provides protection against virus-induced bronchiolitis. These findings support the use of symbiotics in providing protection and treatment of viral infections, particularly viral bronchiolitis, early in life and demonstrate functional benefits of symbiotics in mounting effective antiviral immune responses associated with faster disease resolution.

[0095] Thus, the composition of the invention is, in particular, effective for use in the treatment and / or prevention of a viral infection in an individual.

[0096] Consequently, in a first aspect, the present invention provides a composition for use in the prevention and / or treatment of a viral infection in an individual, the composition comprising Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), and 3'-sialyl-lactose (3SL) and, optionally, 3-fucosyl-lactose (3FL) and / or lacto-N-neotetraose (LNnT).

[0097] In a further aspect, the invention provides the use of a composition according to the invention for the manufacture of a medicament to prevent and / or treat a viral infection in an individual. Petition 870250104625, dated 11 / 14 / 2025, p. 31 / 117 22 / 76

[0098] In a further aspect, the invention provides a method of preventing and / or treating a viral infection in an individual, wherein the method comprises administering to the individual a composition in accordance with the invention.

[0099] Consequently, the composition of the invention is also effective for use in reducing the risk of contracting a viral infection in an individual and / or for use in reducing the symptoms associated with a viral infection in an individual.

[00100] A viral infection can be a gastrointestinal viral infection or a respiratory tract viral infection. A gastrointestinal viral infection can be an intestinal viral infection or a stomach viral infection.

[00101] In a preferred embodiment, the viral infection is a viral infection of the respiratory tract. The viral infection of the respiratory tract may be a viral infection in the upper respiratory tract or in the lower respiratory tract. In a typical embodiment of the invention, the viral infection of the respiratory tract is caused by respiratory syncytial virus (RSV).

[00102] The illness associated with the viral infection will typically be the common cold, influenza (flu), bronchitis, bronchiolitis, pneumonia, sore throat (pharyngitis), sinusitis, non-allergic rhinitis, severe acute respiratory syndrome (SARS), viral croup, otitis media, meningitis, or diarrhea. Usually, when the viral infection is in the respiratory tract, the illness associated with the respiratory tract infection is the common cold, influenza (flu), bronchitis, bronchiolitis, pneumonia, sore throat (pharyngitis), sinusitis, non-allergic rhinitis, severe acute respiratory syndrome (SARS), viral croup, or otitis media. Most often, the illness associated with the viral infection of the respiratory tract is the common cold, influenza (flu), bronchitis, bronchiolitis, or pneumonia. Petition 870250104625, dated 11 / 14 / 2025, p. 32 / 117 23 / 76

[00103] Consequently, in a preferred embodiment of the invention, the composition of the invention is for use in the treatment and / or prevention of a disease associated with a viral infection of the respiratory tract selected from the group consisting of the common cold, influenza (flu), bronchitis, bronchiolitis, and pneumonia. In a more preferred embodiment, the disease associated with the respiratory tract infection is selected from the group consisting of bronchiolitis and pneumonia, in particular, RSV-induced bronchiolitis and / or pneumonia, that is, bronchiolitis and / or pneumonia caused by RSV. In a still more preferred embodiment, the disease associated with the respiratory tract infection is bronchiolitis, in particular, RSV-induced bronchiolitis.

[00104] The symptoms most frequently associated with viral infection, and which can be reduced by the composition of the invention, are lung irritation, lung congestion, excessive mucus production, fever, cough, wheezing, shortness of breath, abdominal cramps, diarrhea or vomiting.

[00105] The infections mentioned above can be caused by a variety of different viruses, including respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza viruses such as influenza A virus (IVA) and / or influenza B virus (IVB), rhinovirus (RV), adenovirus (ADV), metapneumovirus (MPV), bocavirus (BoV), coronavirus (CoV), myxovirus, herpesvirus, enterovirus (EV), paracovirus (PeV), or a combination thereof.

[00106] The composition of the invention is particularly effective in the treatment, prevention, reduction of the risk of contracting, and / or reduction of the symptoms of a viral infection caused by RSV. Thus, the composition of the invention is particularly preferred for use in the treatment, prevention, reduction of the risk of contracting, and / or reduction of the symptoms of RSV-induced bronchiolitis or pneumonia. Petition 870250104625, dated 11 / 14 / 2025, page 33 / 117 24 / 76 induced by RSV.

[00107] The composition of the invention is useful for treating and / or preventing viral infections, in particular respiratory tract infections in a human being of any age. Thus, the human being to be treated with the composition of the invention can be selected from the group consisting of 0 to <1 year (infants), 1 to <3 years (toddlers) and 3 to <6 years (children), including 3 to <5 years (preschoolers). Sustained immune benefit

[00108] Viral infections can also interfere with normal host functioning and may lead to more serious infection-related disorders, including immunopathology following respiratory viral infection (Newton et al, Semin Immunopathol, 2016;38;471-482), such as long-term alterations in the immune system (e.g., inflammatory responses) and subsequent allergic or inflammatory diseases later in life. For example, uncontrolled inflammatory responses following respiratory tract viral infection can lead to pathological remodeling of airway smooth muscle, a hallmark of asthma reported to begin early in life (O'Reilly et al., Jaci, 2013;131;1024-1032), as well as playing a central role in the pathogenesis of chronic obstructive pulmonary disease (COPD; Yan F et al, J. Transi Med, 2018;16;262-270).Thus, severe viral airway infections early in life represent a significant independent risk factor for the subsequent development of respiratory diseases, such as allergic airway diseases (e.g., asthma; Feldman et al., Am J Respir Crit Care Med, 2015;191;34-44) and chronic obstructive pulmonary disease (Savran O et al. Int J Chron Obstruct Pulmon Dis. 2018;13:683-693) later in life.

[00109] Thus, the composition of the invention is, in particular, effective for use in promoting a sustained immune benefit in a Petition 870250104625, dated 11 / 14 / 2025, page 34 / 117 25 / 76 individual.

[00110] Consequently, in another aspect, the invention provides a composition for use in promoting a long-term immune benefit in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL) and 3'-sialyllactose (3SL) and, optionally, 3-fucosyl-lactose (3FL) and / or lacto-N-tetraose (LNnT).

[00111] In a further aspect, the invention provides the use of a composition according to the invention for the manufacture of a medicament to promote a long-term immune benefit in an individual.

[00112] In a further aspect, the invention provides a method for promoting a long-term immune benefit in an individual, wherein the method comprises administering to the individual a composition according to the invention.

[00113] Promoting a long-term immune benefit includes: I. To promote long-term respiratory health; ii. to prevent and / or reduce the risk of sensitization to allergens; and / or iii. to prevent and / or reduce the risk of developing a respiratory condition later in life.

[00114] Appropriately, promoting a long-term immune benefit refers to promoting long-term respiratory health. Appropriately, promoting a long-term immune benefit refers to preventing and / or reducing the risk of sensitization to allergens. Appropriately, promoting a long-term immune benefit refers to preventing and / or reducing the risk of sensitization to allergens. Petition 870250104625, dated 11 / 14 / 2025, p. 35 / 117 26 / 76 reduced risk of developing a respiratory condition later in life.

[00115] As used herein, the phrase long-term encompasses the effect after the intervention or treatment has ended. The long-term effect can be from 1 week to several years, for example, 2 to 4 weeks, 2 to 6 weeks, 2 to 8 weeks, 1 to 6 months, 2 to 12 months, 12 months to 12 years, such as 2 years to 10 years, or 4 years to 5 years, after the intervention or treatment has ended. Therefore, the long-term effect may be present when the individual has reached an age of 3 years or more, preferably 3 to 12 years, more preferably 3 to 10 years, even more preferably 3 to 8, most preferably 3 to 6 years, in particular 3 to 5 years or 3 to 4 years. Appropriately, the long-term effect lasts until the individual is at least 5 years old, or at least 10 years old, at least 20 years old, or at least 30 years old.

[00116] Appropriately, the composition of the invention can prevent a complication associated with a viral infection of the respiratory tract. Appropriately, this effect can be the long-term prevention of a complication associated with a viral infection of the respiratory tract. Such complications may be those associated with the immune systems, such as the inflammatory response, and include immunopathology following viral respiratory infection, such as long-term alterations in the immune system (e.g., long-term alterations in inflammatory responses) and pathological remodeling of airway smooth muscle. These complications may, in turn, predispose the individual to subsequent allergic or inflammatory diseases later in life, such as allergic respiratory diseases or chronic inflammatory diseases of the respiratory tract. Allergic sensitization and respiratory conditions Petition 870250104625, dated 11 / 14 / 2025, page 36 / 117 27 / 76

[00117] Given that viral respiratory tract infections early in life represent a significant independent risk factor for subsequent asthma, recurrent wheezing, and chronic obstructive pulmonary disease later in life (Savran et al, Int J Chron Obstruct, 2015;191;34-44; and Feldman et al. 2015 Am J Respir Crit Care Med, 191;34-44), the composition of the invention is also effective in preventing and / or reducing the risk of developing respiratory conditions such as chronic inflammatory respiratory tract diseases and allergic airway diseases.

[00118] As viral infections, particularly RSV infection, are associated with the subsequent development of allergic airway diseases, such as asthma, later in life (Feldman et al. 2015 Am J Respir Crit Care Med, 191;34-44), the composition of the invention is also effective for use in preventing and / or reducing the risk of sensitization to allergens in the respiratory tract and / or the development of an allergic respiratory tract disease in an individual.

[00119] Along with B. infantis, Bifidobacterium breve is dominant in the stools of breastfed newborns and has a large body of evidence of immune modulation capacity (Bozzi Cionci, N., et al., Nutrients, 2018, 10(11)). This evidence includes beneficial modulation of immune responses in the lung, including reduced airway hyperreactivity, activation of type 2 helper T cells, eosinophilia, and production of allergen-specific antibodies (Hougee, S., et al., Int Arch Allergy Immunol, 2010, 151(2): 107-117).

[00120] The present inventors demonstrate a surprising synergistic effect of HMOs in combination with B. infantis on the establishment of B. breve within fecal fermentation cultures, thus connecting this synergistic effect to pulmonary immunity and, in Petition 870250104625, dated 11 / 14 / 2025, page 37 / 117 28 / 76 in particular, i) preventing and / or treating a viral infection in an individual, ii) promoting a long-term immune benefit in an individual, iii) preventing and / or reducing the risk of sensitization to allergens in the respiratory tract, iv) preventing and / or reducing the risk of developing a respiratory condition in an individual and / or v) preventing and / or reducing the risk of developing asthma.

[00121] Consequently, in another aspect, the invention provides a composition for use i) in the prevention and / or reduction of the risk of sensitization to allergens and / or ii) in the prevention and / or reduction of the risk of developing a respiratory condition in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL) and 3'-sialyl-lactose (3SL) and, optionally, 3'-fucosyl-lactose (3FL) and / or lacto-N-neotetraose (LNnT).

[00122] In another aspect, the invention provides a composition for use in preventing and / or reducing the risk of developing asthma in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL) and 3'-sialyl-lactose (3SL) and, optionally, 3-fucosyl-lactose (3FL) and / or lacto-N-neotetraose (LNnT).

[00123] In a further aspect, the invention provides the use of a composition according to the invention for the manufacture of a medicament to i) prevent and / or reduce the risk of sensitization to allergens and / or ii) prevent and / or reduce the risk of developing a respiratory condition in an individual.

[00124] In a further aspect, the invention provides the use of a composition according to the invention for the manufacture of a Petition 870250104625, dated 11 / 14 / 2025, p. 38 / 117 29 / 76 medication to prevent and / or reduce the risk of developing asthma in an individual.

[00125] In a further aspect, the invention provides a method of i) preventing and / or reducing the risk of sensitization to allergens and / or ii) preventing and / or reducing the risk of developing a respiratory condition in an individual, wherein the method comprises administering to the individual a composition according to the invention.

[00126] In another aspect, the invention provides a method for preventing and / or reducing the risk of developing asthma in an individual, wherein the method comprises administering to the individual a composition in accordance with the invention.

[00127] Respiratory conditions include chronic inflammatory diseases of the respiratory tract and allergic respiratory diseases.

[00128] Chronic inflammatory diseases of the respiratory tract include chronic obstructive pulmonary disease (COPD) and asthma, including allergic asthma and non-allergic asthma.

[00129] COPD is the term for a collection of lung diseases, including chronic bronchitis, emphysema, and chronic obstructive airway disease. People with COPD have difficulty breathing, mainly due to narrowing of their airways.

[00130] Asthma is a chronic respiratory condition marked by inflammation and bronchospasm, causing difficulty breathing. It is usually associated with an allergic reaction or other forms of hypersensitivity. Inflammation and narrowing of the small airways in the lungs cause asthma symptoms, which can be any combination of cough, wheezing, shortness of breath, and chest tightness. Asthma usually develops during childhood, particularly in the preschool stage (3 to 5 years of age).

[00131] Allergic respiratory tract diseases include wheezing Petition 870250104625, dated 11 / 14 / 2025, page 39 / 117 30 / 76 recurrent asthma, including allergic asthma.

[00132] For i) the prevention and / or reduction of the risk of sensitization to allergens and / or ii) the prevention and / or reduction of the risk of developing a respiratory condition in an individual, the composition of the invention is preferably administered to a human being aged 0 to <3 years, preferably 0 to 2 years, more preferably 0 to <1 year, such as 0 to 6 months. This, in turn, prevents and / or reduces the risk of developing a respiratory condition when the individual has reached the age of 3 years or more, preferably 3 to 12 years, more preferably 3 to 10 years, even more preferably 3 to 8, most preferably 3 to 6 years, in particular 3 to 5 years or 3 to 4 years.

[00133] As viral infections, particularly RSV infection, are frequently associated with bacterial co-infection (Thorburn et al, Thorax, 2006;61(7);611-615) or secondary bacterial infection (Sande et al, Nature Communications, 2019;10;2218), including the use of antibiotics, the composition of the invention is also effective for use in preventing or reducing the risk of a bacterial co-infection and / or a secondary bacterial infection associated with respiratory viral infection in a mammal, particularly a human. Pathogenic bacteria typically involved in co-infections or secondary infections include Staphylococcus aureus, Streptococcus pneumoniae, and / or Haemophilus influenzae. Composition

[00134] The present inventors have surprisingly discovered that the combination of Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL) and 3'-sialyl-lactose (3SL) and, optionally, 3-fucosyl-lactose (3FL) and / or Petition 870250104625, dated 11 / 14 / 2025, p. 40 / 117 31 / 76 lacto-N-neotetraose (LNnT) early in life provides protection against virus-induced bronchiolitis and promotes a sustained immune benefit into adulthood (as assessed by reduced susceptibility to pollution-induced allergic airway inflammation).

[00135] As described above, the composition for use according to the invention comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosillactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialillactose (6SL) and 3'-sialyl-lactose (3SL) and, optionally, 3-fucosillactose (3FL) and / or lacto-N-neotetraose (LNnT).

[00136] It is surprising that the specific combination of Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-Ntetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL), lacto-Nneotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL) is effective in protecting against virus-induced bronchiolitis and promoting a sustained immune benefit into adulthood.

[00137] Consequently, in another aspect, the invention provides a composition comprising Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyllactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), 3'-sialyllactose (3SL), lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyllactose (3FL).

[00138] In another aspect, the invention provides a combination comprising or consisting of Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL), lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL). Preferably, the combination Petition 870250104625, dated 11 / 14 / 2025, p. 41 / 117 32 / 76 consists of Bifidobacterium longum infantile subspecies and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL), lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL).

[00139] The combination or composition of the invention may additionally comprise Bifidobacterium animalis subspecies lactis.

[00140] Consequently, in a further aspect, the invention provides a composition comprising Bifidobacterium longum subspecies infantis, Bifidobacterium animalis subspecies lactis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosillactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialillactose (3SL), lacto-N-neotetraose (LNnT) and, optionally, 3-fucosillactose (3FL).

[00141] In a further aspect, the invention provides a combination comprising or consisting of Bifidobacterium longum subspecies infantis, Bifidobacterium animalis subspecies lactis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosillactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialillactose (3SL), lacto-N-neotetraose (LNnT) and, optionally, 3-fucosillactose (3FL). Preferably, the combination consists of Bifidobacterium longum subspecies infantis, Bifidobacterium animalis subspecies lactis and a mixture of HMOs consisting of 2'-fucosyllactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyllactose (6SL), 3'-sialyl-lactose (3SL), lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL). Bifidobacterium longum subspecies infantile

[00142] Bifidobacterium longum is a bacterium of the genus Bifidobacterium that is present in the human gastrointestinal tract. Petition 870250104625, dated 11 / 14 / 2025, page 42 / 117 33 / 76 In 2002, three previously distinct species of Bifidobacterium, B. infantis, B. longum and B. suis, were unified into a single species named B. longum with the infantile, longum and suis biotypes, respectively (Sakata, S., et al., 2002. International journal of systematic and evolutionary microbiology, 52(6), pages 1945 to 1951).

[00143] Any suitable strain of Bifidobacterium longum subspecies infantis may be used in the present invention. Such strains will be well known to those skilled in the art. Suitable strains include Bifidobacterium longum subspecies infantis LMG 11588 (also known as Bifidobacterium longum subspecies infantis NCC3039 or Bifidobacterium longum subspecies infantis ATCC 17930) and Bifidobacterium longum subspecies infantis ATCC 15697 (also known as Bifidobacterium longum subspecies infantis NCC 3078).

[00144] Bifidobacterium longum subspecies infantis may be a strain with at least 99% (suitably, at least 99.9%) of ANI with the Bifidobacterium longum subspecies infantis strain known to those skilled in the art.

[00145] Suitablely, Bifidobacterium longum subspecies infantis has at least 99% (suitably, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9%) of ANI with Bifidobacterium longum subspecies infantis LMG 11588 (also known as Bifidobacterium longum subspecies infantis NCC3039 or Bifidobacterium longum subspecies infantis ATCC 17930). Preferably, Bifidobacterium longum subspecies infantis has at least 99.9% of ANI with Bifidobacterium longum subspecies infantis LMG 11588. Petition 870250104625, dated 11 / 14 / 2025, page 43 / 117 34 / 76

[00146] An example of a microorganism genome that has at least 99.9% ANI with B. longum subspecies infantis LMG 11588 can be found at PATRIC (https: / / www.patricbrc.org), genome ID 1678.111. Thus, appropriately, B. longum subspecies infantis with genome PATRIC ID 1678.111 can be used in the present invention.

[00147] Bifidobacterium longum subspecies infantis LMG 11588 is sold by the Belgian Coordinated Collections of Microorganisms (BCCM) under the accession number LMG: LMG 11588.

[00148] Bifidobacterium longum subspecies infantis ATCC 15697 is sold by the American Type Culture Collection (ATCC) under accession number ATCC 15697.

[00149] The composition or combination according to the invention may contain from 10³ to 10¹² CFU of Bifidobacterium longum subspecies infantis, more preferably between 10⁷ and 10¹² CFU, as well as between 10⁸ and 10¹⁰ CFU of Bifidobacterium longum subspecies infantis per gram of composition or combination on a dry weight basis. Suitablely, Bifidobacterium longum subspecies infantis is administered to the individual in an amount of at least about 10⁶ CFU / day, at least about 10⁷ CFU / day, or at least about 10⁸ CFU / day. Suitablely, Bifidobacterium longum subspecies infantis is administered to the individual in an amount of about 10¹² CFU / day or less, about 10¹¹ CFU / day or less, or about 10¹⁰ CFU / day or less.

[00150] In one embodiment, Bifidobacterium longum subspecies infantis is viable. Bifidobacterium animalis subspecies lactis

[00151] Any strain of Bifidobacterium animalis subspecies lactis (B. lactis) may be used in the present invention. Such strains will be well known to those skilled in the art. Suitable strains Petition 870250104625, dated 11 / 14 / 2025, page 44 / 117 35 / 76 include Bifidobacterium animalis subspecies lactis CNCM I-3446.

[00152] Bifidobacterium animalis subspecies lactis may be a strain with at least 99% (suitably, at least 99.9%) of ANI with a strain of Bifidobacterium animalis subspecies lactis known to those skilled in the art.

[00153] Suitablely, Bifidobacterium animalis subspecies lactis has at least 99% (suitably, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, at least 99.9%) of ANI with Bifidobacterium animalis subspecies lactis CNCM I-3446. Preferably, Bifidobacterium animalis subspecies lactis has at least 99.9% of ANI with Bifidobacterium animalis subspecies lactis CNCM I-3446.

[00154] Bifidobacterium lactis CNCM I-3446 was deposited at the Collection Nationale de Cultures de Microorganismes (CNCM), Institut Pasteur (INSTITUT PASTEUR, 25 RUE DU DOCTEUR ROUX, F75724 PARIS CEDEX 15, FRANCE) by NESTEC SA (NESTEC SA, AVENUE NESTLE 55, CH-1800 VEVEY) according to the The Budapest Treaty of June 7, 2005, received the deposit number CNCM I-3446.

[00155] The composition or combination according to the invention may contain from 10³ to 10¹² cfu of Bifidobacterium animalis subspecies lactis, more preferably between 10⁷ and 10¹² cfu, as well as between 10⁸ and 10¹⁰ cfu of Bifidobacterium animalis subspecies lactis per gram of composition or combination on a dry weight basis. Suitablely, Bifidobacterium animalis subspecies lactis is administered to the individual in an amount of at least about 10⁶ cfu / day, at least about 10⁷ cfu / day, or at least about 10⁸ cfu / day. Suitablely, Bifidobacterium animalis subspecies lactis is administered to the individual in an amount of about 10¹² Petition 870250104625, dated 11 / 14 / 2025, page 45 / 117 36 / 76 CFU / day or less, approximately 1011 CFU / day or less, or approximately 1010 CFU / day or less.

[00156] The composition or combination according to the invention may contain from 103 to 1012 CFU of bifidobacteria (for example, a combination of Bifidobacterium longum subspecies infantis and Bifidobacterium animalis subspecies lactis), more preferably between 107 and 1012 CFU, as well as between 108 and 1010 CFU of bifidobacteria (for example, a combination of Bifidobacterium longum subspecies infantis and Bifidobacterium animalis subspecies lactis) per g of composition or combination on a dry weight basis. Appropriately, bifidobacteria (e.g., a combination of Bifidobacterium longum subspecies infantis and Bifidobacterium animalis subspecies lactis) are administered to the individual in an amount of at least about 10⁶ CFU / day, at least about 10⁷ CFU / day, or at least about 10⁸ CFU / day.Appropriately, bifidobacteria (e.g., a combination of Bifidobacterium longum subspecies infantis and Bifidobacterium animalis subspecies lactis) are administered to the individual in an amount of approximately 10¹² CFU / day or less, approximately 10¹¹ CFU / day or less, or approximately 10¹⁰ CFU / day or less.

[00157] In one embodiment, Bifidobacterium animalis subspecies lactis is viable. HMO Mixture

[00158] The composition or combination of the invention comprises a mixture of HMOs.

[00159] In some embodiments, the HMO mixture consists of 2-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL) and 3'-sialyl-lactose (3SL).

[00160] In some embodiments, the HMO mixture consists of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), Petition 870250104625, dated 11 / 14 / 2025, p. 46 / 117 37 / 76 6'-sialyllactose (6SL), 3'-sialyllactose (3SL) and 3-fucosyllactose (3FL).

[00161] In some embodiments, the HMO mixture consists of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and lacto-N-neotetraose (LNnT).

[00162] In some embodiments, the HMO mixture consists of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL), 3-fucosyl-lactose (3FL) and lacto-N-neotetraose (LNnT).

[00163] In one embodiment, the HMO mixture comprises 2FL in an amount of 16% by weight to 85% by weight. Suitablely, the HMO mixture may comprise 2FL in an amount of 31% by weight to 82% by weight, preferably 41% by weight to 70% by weight. Suitablely, the HMO mixture may comprise 2FL in an amount of 16% by weight to 69% by weight, preferably 22% by weight to 59% by weight. Suitablely, the HMO mixture may comprise 2FL in an amount of 34% by weight to 85% by weight, preferably 40% by weight to 71% by weight. Ideally, the HMO mixture may comprise 2FL in an amount of 20% by weight to 60% by weight, preferably 22% by weight to 55% by weight.

[00164] In one embodiment, the HMO mixture comprises LNT in an amount of 4% by weight to 40% by weight. Suitably, the HMO mixture may comprise LNT in an amount of 10% by weight to 27% by weight, preferably 14% by weight to 23% by weight. Suitably, the HMO mixture may comprise LNT in an amount of 9% by weight to 24% by weight, preferably 12% by weight to 21% by weight. Suitably, the HMO mixture may comprise LNT in an amount of 10% by weight to 40% by weight, preferably 12% by weight to 26% by weight. Petition 870250104625, dated 11 / 14 / 2025, page 47 / 117 38 / 76 Ideally, the HMO mixture may comprise LNT in an amount of 4% by weight to 30% by weight, preferably 6% by weight to 20% by weight.

[00165] In one embodiment, the HMO mixture comprises DFL in an amount of 1% by weight to 14% by weight. Suitablely, the HMO mixture may comprise DFL in an amount of 4% by weight to 11% by weight, preferably 6% by weight to 10% by weight. Suitablely, the HMO mixture may comprise DFL in an amount of 2% by weight to 10% by weight, preferably 3% by weight to 8% by weight. Suitablely, the HMO mixture may comprise DFL in an amount of 4% by weight to 14% by weight, preferably 5% by weight to 10% by weight. Ideally, the HMO mixture may comprise DFL in an amount of 1% by weight to 12% by weight, preferably 2% by weight to 8% by weight.

[00166] In one embodiment, the HMO mixture comprises 6SL and 3SL combined in an amount of 7% by weight to 34% by weight. Suitablely, the HMO mixture may comprise 6SL and 3SL combined in an amount of 9% by weight to 34% by weight, preferably 11% by weight to 29% by weight. Suitablely, the HMO mixture may comprise 6SL and 3SL combined in an amount of 8% by weight to 26% by weight, preferably 11% by weight to 22% by weight. Suitablely, the HMO mixture may comprise 6SL and 3SL combined in an amount of 9% by weight to 31% by weight, preferably 10% by weight to 28% by weight. Ideally, the HMO mixture may comprise 6SL and 3SL combined in an amount of 7% by weight to 23% by weight, preferably 8% by weight to 22% by weight.

[00167] In one embodiment, the HMO mixture comprises 3FL in an amount of 10% by weight to 50% by weight. Petition 870250104625, dated 11 / 14 / 2025, page 48 / 117 39 / 76 Suitablely, the HMO mixture may comprise 3FL in an amount of 18% by weight to 50% by weight, preferably 11% by weight to 43% by weight. Suitablely, the HMO mixture may comprise 3FL in an amount of 10% by weight to 50% by weight, preferably 13% by weight to 46% by weight.

[00168] In one embodiment, the HMO mixture comprises LNnT in an amount of 6% by weight to 30% by weight. Suitablely, the HMO mixture may comprise LNnT in an amount of 6% by weight to 30% by weight, preferably 7% by weight to 22% by weight. Suitablely, the HMO mixture may comprise LNnT in an amount of 3% by weight to 25% by weight, preferably 5% by weight to 20% by weight.

[00169] In some forms, the HMO mixture consists essentially of: i. 31% by weight to 82% by weight of 2FL; ii. 10% by weight to 27% by weight of LNT; iii. 4% by weight to 11% by weight of DFL; and iv. 9% by weight to 34% by weight of 6SL and 3SL combined.

[00170] In some preferred modalities, the HMO mixture consists essentially of: i. 41% by weight to 70% by weight of 2FL; ii. 14% by weight to 23% by weight of LNT; iii. 6% by weight to 10% by weight of DFL; and iv. 11% by weight to 29% by weight of 6SL and 3SL combined.

[00171] In some forms, the HMO mixture consists essentially of: i. 16% by weight to 69% by weight of 2FL; ii. 9% by weight to 24% by weight of LNT; iii. 2% by weight to 10% by weight of DFL; iv. 8% by weight to 26% by weight of 6SL and 3SL combined; and Petition 870250104625, dated 11 / 14 / 2025, page 49 / 117 40 / 76 v. 18% by weight to 50% by weight of 3FL.

[00172] In some preferred modalities, the HMO mixture consists essentially of: i. 22% by weight to 59% by weight of 2FL; ii. 12% by weight to 21% by weight of LNT; iii. 3% by weight to 8% by weight of DFL; iv. 11% by weight to 22% by weight of 6SL and 3SL combined; and v. 11% by weight to 43% by weight of 3FL.

[00173] In some forms, the HMO mixture consists essentially of: i. 34% by weight to 85% by weight of 2FL; ii. 10% by weight to 40% by weight of LNT; iii. 4% by weight to 14% by weight of DFL; iv. 9% by weight to 31% by weight of 6SL and 3SL combined; and v. 6% by weight to 30% by weight of LNnT.

[00174] In some preferred modalities, the HMO mixture consists essentially of: i. 40% by weight to 71% by weight of 2FL; ii. 12% by weight to 26% by weight of LNT; iii. 5% by weight to 10% by weight of DFL; and iv. 10% by weight to 28% by weight of 6SL and 3SL combined; and v. 7% by weight to 22% by weight of LNnT.

[00175] In some forms, the HMO mixture consists essentially of: i. 20% by weight to 60% by weight of 2FL; ii. 4% by weight to 30% by weight of LNT; iii. 1% by weight to 12% by weight of DFL; iv. 7% by weight to 23% by weight of 6SL and 3SL combined; v. 10% by weight to 50% by weight of 3FL; and vi. 3% by weight to 25% by weight of LNnT. Petition 870250104625, dated 11 / 14 / 2025, page 50 / 117 41 / 76

[00176] In some preferred modalities, the HMO mixture consists essentially of: i. 22% by weight to 55% by weight of 2FL; ii. 6% by weight to 20% by weight of LNT; iii. 2% by weight to 8% by weight of DFL; iv. 8% by weight to 22% by weight of 6SL and 3SL combined; v. 13% by weight to 46% by weight of 3FL and vi. 5% by weight to 20% by weight of LNnT.

[00177] When the composition or combination is in liquid form, the total HMO concentration is typically in the range of 0.5 to 10 g / l, preferably in the range of 1 to 7.5 g / l. Specific examples of the total HMO concentration level when the composition or combination is in liquid form include 1 to 5 g / l, 1 to 4 g / l, 2 to 5 g / l, 1 to 3 g / l, or 2 to 4 g / l.

[00178] When the composition or combination is in solid form, the total HMO concentration is typically in the range of 0.35 to 7% by weight (g total HMO / 100 g dry composition), preferably in the range of 0.35 to 5% by weight. Specific examples of the total HMO concentration level when the composition or combination is in dry form include 0.5 to 3.5% by weight (g total HMO per 100 g dry composition), 0.5 to 2.5% by weight, 1 to 3.5% by weight, 0.5 to 2% by weight, or 1 to 2.5% by weight. Individual

[00179] In some forms, the individual is a mammal, such as a human being.

[00180] In some embodiments, the nutritional composition according to the invention is intended for use in infants, toddlers or children.

[00181] In one modality, the individual is a baby. In one modality, the individual is a toddler. In one modality, Petition 870250104625, dated 11 / 14 / 2025, page 51 / 117 42 / 76 the individual is a child.

[00182] The composition according to the invention is intended for use in infants or young children. It is particularly suitable for children under 6 months of age.

[00183] In general, formula-fed babies have an underdeveloped immune system compared to adults and are more prone to viral infections than breastfed babies, and the younger the baby, the less developed the immune system. Consequently, the formula is particularly useful for preterm and / or low or very low birth weight babies, as these babies are even more vulnerable and prone to viral infections. In another particularly interesting application, the formula is used in babies born via cesarean section. Babies born via cesarean section are born in a hospital environment with more pathogens against which antibodies, transferred from mother to baby, are not effective. Furthermore, the administration of antibiotics is a recommended medical practice for cesarean section deliveries in order to prevent infection.Such interventions are potent disruptors of microbial communities (of the mother or child), and antibiotic treatment early in life is associated with an increased risk of developing immune-mediated disorders later in life. Babies born by cesarean section have delayed and less optimal colonization of the large intestine and are therefore also more prone to infections.

[00184] Babies, toddlers, or children may be born at term or preterm. In a specific embodiment, the nutritional composition of the invention is intended for use in preterm infants, toddlers, or young children. Premature babies may be at greater risk of insufficient nutrient intake. Petition 870250104625, dated 11 / 14 / 2025, page 52 / 117 43 / 76 impaired lean body mass growth, fat accumulation in the visceral area, and metabolic disease later in life. Thus, in one embodiment, the nutritional composition of the invention is intended for use in preterm infants.

[00185] In one modality, the individual is a baby or young child who was born small for gestational age or with low birth weight.

[00186] Babies or young children with low birth weight may or may not be premature, and similarly, babies or young children who were small for gestational age may or may not be premature.

[00187] The nutritional composition of the present invention can also be used in a baby or young child who was born by cesarean section or who was born vaginally.

[00188] All babies and young children can benefit from the invention, as they are all, or may be at a certain age, susceptible to acquiring an unbalanced gut / gastrointestinal tract microbiota.

[00189] In some advantageous embodiments of the invention, the nutritional composition is intended for use in infants or young children with a fragile or unbalanced microbiota or microbiota dysbiosis, such as preterm infants, infants born by cesarean section, infants born small for gestational age or with low birth weight, hospitalized infants / young children, infants / young children treated or who have been treated with antibiotics and / or infants / young children who suffer or have suffered from gastrointestinal tract infection and / or gastrointestinal tract inflammation.

[00190] In fact, it is anticipated that the composition of the invention may be even more beneficial for newborns with gut microbiota. Petition 870250104625, dated 11 / 14 / 2025, page 53 / 117 44 / 76 possibly impaired gastrointestinal tract or frail infants / young children (such as prematurely born infants and / or infants born by cesarean section). It is also anticipated that the composition of the invention may be even more beneficial for infants / young children exhibiting intestinal disorders (such as diarrhea, infections or colic), especially after birth, for example, during the first 4 weeks after birth.

[00191] In embodiments of the invention, infants born prematurely or born by cesarean section or born small for gestational age or with low birth weight or exhibiting unbalanced or abnormal gastrointestinal tract microbiota or suffering or having suffered gastrointestinal tract infection and / or gastrointestinal tract inflammation are the target of the composition of the present invention, especially when the infants are 0 to 6 months old. Without adhering to theory, it is believed that younger infants benefit even more from the composition of the invention, especially when the infants have (or are at risk of having) an unbalanced gut microbiota and / or have a fragile health condition (as exemplified by the conditions cited above).

[00192] The nutritional composition can be administered (or provided or fed) at any age for a period that depends on the needs.

[00193] In one embodiment, infants or toddlers are 0 to 36 months old, as well as 0 to 12 months or 0 to 6 months old. It is anticipated that the composition of the invention may be even more beneficial for infants just after birth (0 to 4 weeks or 0 to 8 weeks), as their intestinal tract may be more fragile.

[00194] The mammal to be treated is preferably a human being, but the mammal can also be a non-human mammal. Petition 870250104625, dated 11 / 14 / 2025, p. 54 / 117 45 / 76 human, as a non-human mammal selected from the group consisting of pig, cow, horse, dog, cat, goat, sheep and rabbit.

[00195] In other forms, the individual is preferably a juvenile animal, and the animal is a pet.

[00196] A pet can be a mammal, such as dogs or cats, or rodents, such as mice, rats and guinea pigs, rabbits, etc. In some forms, the pet is a small dog breed.

[00197] The term young person can refer to an individual who has not yet reached adulthood.

[00198] In some embodiments, the nutritional composition according to the invention may be for use before and / or during the weaning period.

[00199] In some embodiments, the nutritional composition according to the invention is for use in an individual at risk and / or in need.

[00200] The individual at risk and / or in need may be bottle-fed and / or formula-fed.

[00201] In one embodiment, the composition of the invention is provided to the individual as a supplementary composition to breast milk. In some embodiments, the individual receives breast milk for at least the first 2 weeks, the first month, or the first 1, 2, 4, or 6 months. In one embodiment, the nutritional composition of the invention is provided to the individual after the mother's breastfeeding period or is provided along with such breastfeeding period with breast milk. In another embodiment, the composition is provided to the individual as the sole or primary nutritional composition for at least a period of time, for example after the 1st, 2nd, or 4th month of life, for at least 1, 2, 4, or 6 months. In a Petition 870250104625, dated 11 / 14 / 2025, p. 55 / 117 46 / 76 embodiment, the nutritional composition of the invention is a complete nutritional composition (satisfying all or most of the individual's nutritional needs). In another embodiment, the nutritional composition of the invention is a supplement or fortifier intended, for example, to supplement human milk or to supplement an infant formula or a follow-on formula. Nutritional composition

[00202] In some embodiments, the composition of the invention is in the form of a nutritional composition.

[00203] The nutritional composition according to the invention may be, for example, an infant formula, an initial infant formula, a transition or follow-up formula, a growing-up milk, an infant food, an infant cereal composition, a fortifier, such as a human milk fortifier, a supplement, a pet food or a pet food supplement. In some specific embodiments, the composition of the invention is an infant formula, a fortifier or a supplement that may be intended for the first 4 or 6 months of age. In a preferred embodiment, the nutritional composition of the present invention is an infant formula.

[00204] In some other embodiments, the nutritional composition of the present invention is a fortifier. The fortifier may be a breast milk fortifier (e.g., a human milk fortifier) ​​or a formula fortifier, such as an infant formula fortifier or a follow-on / follow-up formula fortifier.

[00205] When the nutritional composition is a supplement, it can be provided in the form of unit doses. In such cases, it is particularly useful to define the amount of oligosaccharides and probiotics in terms of the daily dose to be administered to the baby. Petition 870250104625, dated 11 / 14 / 2025, pp. 56 / 117 47 / 76 young child or to the child.

[00206] When the nutritional composition is a supplement, it may comprise the mixture of HMOs as described herein and B. infantis and no other additional nutrients besides the excipients necessary to obtain a stable nutritional composition.

[00207] The nutritional composition of the present invention may be in solid (e.g., powder), liquid, or gelatinous form. In a particular embodiment, the nutritional composition is a supplement, wherein the supplement is in powder form and is supplied in a sachet, preferably a sachet containing 0.1 to 20 g per sachet, for example, 1 to 10 g per sachet, or in the form of a syrup, preferably a syrup with a total solids concentration of 5 to 75 g / 100 ml (5 to 75% (w / v)). When the supplement is in powder form, it may comprise a carrier. It is preferred, however, that the supplement be without a carrier. When the supplement is in the form of a syrup, the components are preferably dissolved or suspended in citrate-acidified water.

[00208] In a particular embodiment, the nutritional composition according to the invention is a hypoallergenic composition.In another specific embodiment, the composition according to the invention is a hypoallergenic nutritional composition. Other ingredients

[00209] The composition or combination according to the present invention may also comprise other types of oligosaccharide(s), polysaccharides and / or fiber(s) and / or precursor(s) thereof. The other oligosaccharide and / or fiber and / or precursor thereof may be selected from a list comprising human milk oligosaccharides (HMOs), galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), xylo-oligosaccharides (XOS), cellulose oligosaccharides (COS), arabinoxylans, arabinans, xylans, inulin, Petition 870250104625, dated 11 / 14 / 2025, pp. 57 / 117 48 / 76 polydextrose, beta-glucans, pectins and any combination thereof and any preparations derived therefrom (e.g., partial hydrolysis). They may be present in an amount between 0 and 10%, by weight, of the composition. In a specific embodiment, the nutritional composition may also contain at least one bovine milk-derived oligosaccharide (BMO).

[00210] Additional HMOs that may be included in the nutritional composition according to the present invention may be selected from the group consisting of lacto-N-fucopentaose (for example, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V), lacto-N-fucopentaose, lacto-N-difuco-hexaose I, fucosylacto-N-hexaose, fucosylacto-N-neo-hexaose, difucosyl-lacto-N-hexaose I, difucosyl-lacto-N-neo-hexaose II, paralacto-N-neo-hexaose (para-LNnH), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose, para-lacto-N-neo-hexaose, lacto-N-noctaose, lacto-N-neo-octaose, iso-lacto-N-octaose, para-lacto-neo-octaose, lacto-N-decaose, and any combination thereof.

[00211] In some embodiments, the composition or combination according to the invention comprises at least one additional HMO.

[00212] In other embodiments, the composition or combination according to the present invention is devoid of any additional HMOs. Thus, the mixture of prebiotic oligosaccharides as described herein may be the only HMOs in the composition or combination of the invention.

[00213] The composition or combination of the present invention may further comprise at least one additional probiotic (or probiotic strain), such as at least one additional probiotic bacterial strain. Petition 870250104625, dated 11 / 14 / 2025, pp. 58 / 117 49 / 76

[00214] The most commonly used probiotic microorganisms are mainly bacteria and yeasts from the following genera: Lactobacillus spp., Lacticaseibacillus spp., Limosilactobacillus spp., Streptococcus spp., Enterococcus spp., Bifidobacterium spp. and Saccharomyces spp.

[00215] In some specific embodiments, the probiotic is a probiotic bacterial strain. In some specific embodiments, they are particularly bifidobacteria and / or lactobacilli.

[00216] Suitable probiotic bacterial strains include Lactobacillus rhamnosus ATCC 53103 available from Valio Oy of Finland under the trademark LGG, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus paracasei CNCM I-2116, Lactobacillus johnsonii CNCM I-1225, Streptococcus salivarius DSM 13084 sold by BLIS Technologies Limited of New Zealand under the designation KI2, Bifidobacterium lactis sold, among others, by the company Christian Hansen of Denmark under the trademark Bb 12, B. longum CNCM I-2618 (B. longum NCC2705), Bifidobacterium breve sold by Danisco under the trademark Bb-03, Bifidobacterium breve sold by Morinaga under the trademark M-16V, Bifidobacterium infantis sold, for example, by Procter & Gamble Co. under the trademark Bifantis, and Bifidobacterium breve sold by Institut Rosell (Lallemand) under the trademark R0070.

[00217] The composition or combination according to the invention may contain from 10e3 to 10e12 cfu of at least one (additional) probiotic strain, more preferably between 10e7 and 10e12 cfu, as well as between 10e8 and 10e10 cfu of probiotic strain per g of composition or combination on a dry weight basis.

[00218] In one embodiment, the probiotics are viable. In another embodiment, the probiotics are non-replicating or inactivated. Petition 870250104625, dated 11 / 14 / 2025, pp. 59 / 117 50 / 76 There may be viable probiotics and inactivated probiotics in some other formulations. Probiotic components and metabolites may also be added.

[00219] The nutritional composition according to the invention generally contains a protein source. The protein may be in an amount of 1.6 to 3 g per 100 kcal. In some embodiments, particularly when the composition is intended for premature infants, the amount of protein may be between 2.4 and 4 g / 100 kcal or more than 3.6 g / 100 kcal. In some other embodiments, the amount of protein may be below 2.0 g per 100 kcal, for example, between 1.8 and 2 g / 100 kcal, or in an amount below 1.8 g per 100 kcal.

[00220] Protein sources based on whey, casein, and mixtures thereof, as well as soy-based protein sources, may be used. With regard to whey proteins, the protein source may be based on acid whey or sweet whey, or mixtures thereof, and may include alpha-lactalbumin and beta-lactoglobulin in any desired proportions.

[00221] In some advantageous embodiments, the protein source is predominantly whey (i.e., more than 50% of the proteins come from whey proteins, such as 60% or 70%).

[00222] Proteins can be intact or hydrolyzed, or they can be a mixture of intact or hydrolyzed proteins. By the term intact it is understood that the main part of the proteins is intact, that is, the molecular structure is not altered, for example, at least 80% of the proteins are not altered, as at least 85% of the proteins are not altered, preferably at least 90% of the proteins are not altered, even more preferably at least 95% of the proteins are not altered, as at least 98% of the proteins are not altered. In a specific embodiment, 100% Petition 870250104625, dated 11 / 14 / 2025, pp. 60 / 117 51 / 76 of the proteins are not altered.

[00223] The term hydrolysate means, in the context of the present invention, a protein that has been hydrolyzed or broken down into its component amino acids. Proteins may be totally or partially hydrolyzed. Supplementation with partially hydrolyzed proteins (degree of hydrolysis between 2% and 20%) may be desirable, for example, for infants or young children who are believed to be at risk for developing cow's milk allergy. If hydrolyzed proteins are required, the hydrolysis process can be carried out as desired and as known in the art. For example, whey protein hydrolysates can be prepared by enzymatic hydrolysis of the whey fraction in one or more steps. It has been found that, if the whey fraction used as the starting material is substantially lactose-free, the protein undergoes much less lysine lock-up during the hydrolysis process.This allows the extent of lysine blockade to be reduced from about 15% by weight of total lysine to less than about 10% by weight of lysine; for example, about 7% by weight of lysine, which greatly improves the nutritional quality of the protein source.

[00224] In one embodiment of the invention, at least 70% of the proteins are hydrolyzed, preferably at least 80% of the proteins are hydrolyzed, as at least 85% of the proteins are hydrolyzed, more preferably at least 90% of the proteins are hydrolyzed, as at least 95% of the proteins are hydrolyzed, particularly at least 98% of the proteins are hydrolyzed. In a specific embodiment, 100% of the proteins are hydrolyzed.

[00225] In one specific embodiment, the proteins in the nutritional composition are hydrolyzed, fully hydrolyzed, or Petition 870250104625, dated 11 / 14 / 2025, pp. 61 / 117 52 / 76 partially hydrolyzed. The degree of hydrolysis (DH) of the protein can be between 8 and 40, or between 20 and 60, or between 20 and 80, or more than 10, 20, 40, 60, 80 or 90.

[00226] The protein component may alternatively be replaced by a synthetic amino acid or mixture, for example, for premature or low birth weight infants.

[00227] In one specific embodiment, the nutritional composition or growing-up milk according to the invention is a hypoallergenic composition. In another specific embodiment, the composition according to the invention is a hypoallergenic nutritional composition or growing-up milk.

[00228] The nutritional composition according to the present invention generally contains a carbohydrate source. This is particularly preferred in the case where the nutritional composition of the invention is an infant formula. In this case, any carbohydrate source conventionally found in infant formulas, such as lactose, sucrose, maltodextrin, starch, and mixtures thereof, may be used, although one of the preferred carbohydrate sources is lactose.

[00229] The nutritional composition according to the present invention generally contains a lipid source. This is particularly relevant if the nutritional composition of the invention is an infant formula. In this case, the lipid source can be any lipid or fat that is suitable for use in infant formulas. Some suitable fat sources include palm oil, structured triglyceride oil, high oleic sunflower oil, and high oleic safflower oil, medium-chain triglyceride oil. Essential fatty acids, such as linoleic acid and α-linolenic acid, may also be added, in addition to small amounts of oils containing high amounts of fatty acids. Petition 870250104625, dated 11 / 14 / 2025, pp. 62 / 117 53 / 76 pre-formed arachidonic and docosahexaenoic acids, such as fish oils or microbial oils. The fat source may have a ratio of n-6 fatty acids to n-3 fatty acids of about 5:1 to about 15:1; for example, from about 8:1 to about 10:1.

[00230] The nutritional composition of the invention may also contain all vitamins and minerals considered essential in the daily diet and in nutritionally significant quantities. Minimum requirements for certain vitamins and minerals have been established. Examples of minerals, vitamins, and other micronutrients optionally present in the composition of the invention include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin E, vitamin K, vitamin C, vitamin D, folic acid, inositol, niacin, biotin, pantothenic acid, choline, calcium, phosphorus, iodine, iron, magnesium, copper, zinc, manganese, chlorine, potassium, sodium, selenium, chromium, molybdenum, taurine, and L-carnitine. Minerals are normally added in the form of salt. The presence and quantities of specific minerals and other specific vitamins will vary depending on the intended population.

[00231] If necessary, the nutritional composition of the invention may contain emulsifiers and stabilizers, such as soy, lecithin, citric acid esters of mono- and diglycerides, and the like.

[00232] The nutritional composition of the invention may also contain other substances that may have a beneficial effect, such as nucleotides, nucleosides and the like.

[00233] The nutritional composition of the invention may also contain carotenoid(s). In some specific embodiments of the invention, the nutritional composition of the invention does not comprise any carotenoid. Manufacturing a nutritional composition

[00234] The nutritional composition according to the invention may Petition 870250104625, dated 11 / 14 / 2025, pp. 63 / 117 54 / 76 can be prepared in any suitable manner. A composition will now be described as an example.

[00235] For example, a formula, such as an infant formula, can be prepared by mixing the protein source, carbohydrate source, and fat source in appropriate proportions. If used, emulsifiers can be added at this point. Vitamins and minerals can be added at this point, but they are usually added later to prevent thermal degradation. Any lipophilic vitamins and emulsifiers, and the like, can be dissolved in the fat source before blending. Water, preferably reverse osmosis water, can then be mixed in to form a liquid mixture. The water temperature is conveniently in the range of about 50°C to about 80°C to help disperse the ingredients. Commercially available blenders can be used to form the liquid mixture.

[00236] The oligosaccharide(s) may be added at this stage, especially if the final product is to be in liquid form. If the final product is a powder, they may also be added at this stage, if desired.

[00237] The liquid mixture is then homogenized, for example, in two stages.

[00238] The liquid mixture can then be thermally treated to reduce bacterial loads by rapidly heating the liquid mixture to a temperature in the range of about 80°C to about 150°C for about 5 seconds to about 5 minutes, for example. This can be accomplished by means of steam injection, autoclave or heat exchanger, for example, a plate heat exchanger.

[00239] So, the liquid mixture can be cooled to between about Petition 870250104625, dated 11 / 14 / 2025, pp. 64 / 117 55 / 76 of 60°C and about 85°C, for example, by flash cooling. The liquid mixture can then be homogenized again, for example, in two stages between about 10 MPa and about 30 MPa in the first stage, and between about 2 MPa and about 10 MPa in the second stage. The homogenized mixture can then be further cooled to add any heat-sensitive components, such as vitamins and minerals. The pH and solids content of the homogenized mixture are conveniently adjusted at this point.

[00240] If the final product is a powder, the homogenized mixture is transferred to a suitable drying apparatus, such as a spray dryer or freeze dryer, and converted into powder. The powder must have a moisture content of less than about 5% by weight. The oligosaccharide(s) may also, or alternatively, be added at this stage by dry mixing or by blending them into a crystal syrup form, along with the probiotic strain(s), and the mixture is spray-dried or freeze-dried.

[00241] If a liquid composition is preferred, the homogenized mixture can be sterilized and then aseptically filled into suitable containers, or it can first be filled into the containers and then retort-filled.

[00242] In another embodiment, the composition of the invention may be a supplement. The supplement may be in the form of tablets, capsules, lozenges or a liquid, for example. The supplement may also contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film-forming agents, encapsulation agents / materials, wall / shell materials, matrix compounds, coatings, emulsifiers, surface-active agents, solubilizing agents (oils, fats, waxes, lecithins, etc.), adsorbents, carriers, fillers, co-compounds, agents Petition 870250104625, dated 11 / 14 / 2025, pp. 65 / 117 56 / 76 dispersants, wetting agents, processing aids (solvents), flow agents, flavor masking agents, bulking agents, gelling agents and gel-forming agents. The supplement may also contain conventional pharmaceutical additives and auxiliary compounds, excipients and diluents, including, but not limited to, water, gelatin of any origin, vegetable gums, lignin sulfonate, talc, sugars, starch, gum arabic, vegetable oils, polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifying agents, buffering agents, lubricants, colorants, humectants, fillers and the like.

[00243] Additionally, the supplement may contain an organic or inorganic carrier material suitable for oral or parenteral administration, as well as vitamins, trace minerals and other nutrients, in accordance with the recommendations of government bodies such as the USRDA.

[00244] This disclosure is not limited to the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein may be used in the practice or testing of embodiments of this disclosure. Numerical ranges are inclusive of the numbers defining the range. Unless otherwise indicated, any nucleic acid sequences are written from left to right in the 5' to 3' orientation; amino acid sequences are written from left to right in the amino to carboxy orientation, respectively.

[00245] When a range of values ​​is provided, it is understood that each intervening value is also specifically revealed, up to the tenth of a unit of the lower limit, unless the context clearly determines otherwise, between the upper and lower limits of that range. Each smaller range between any stated value or intervening value in a stated range and any other value Petition 870250104625, dated 11 / 14 / 2025, pp. 66 / 117 The 57 / 76 declared value or intervening value in that declared range is included in this disclosure. The upper and lower limits of those smaller ranges may be independently included in or excluded from the range, and each range where any of the limits, neither of the limits, or both limits are included in the smaller ranges is also included in this disclosure, subject to any limit specifically excluded in the declared range. When the declared range includes one or both limits, the ranges that exclude either or both of those limits are also included in this disclosure.

[00246] It should be mentioned that, as used here and in the attached claims, the singular forms a, an, oea include plural references, unless the context clearly dictates otherwise.

[00247] The terms comprising, includes, and comprised of, as used herein, are synonymous with including, includes, or containing, contains, and are inclusive or not limited to and do not exclude additional members, elements, or method steps not mentioned. The terms comprising, includes, and comprised of also include the term consisting of.

[00248] Unless otherwise indicated, the practice of the present invention will employ conventional techniques of chemistry, biochemistry, molecular biology, microbiology, and immunology, which are within the capabilities of a person skilled in the art. These techniques are explained in the literature. See, for example, Sambrook, J., Fritsch, EF, and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press; Ausubel, FM et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, chapters 9, 13, and 16, John Wiley & Sons; Roe, B., J., Crabtree, J., and Kahn, A. (1996), Isolation and Sequencing of DNA: Essential Techniques, Petition 870250104625, dated 11 / 14 / 2025, pp. 67 / 117 58 / 76 John Wiley & Sons; Polak, J.M. and McGee, J.O.D. (1990) In Situ Hybridization: Principles and Practice, Oxford University Press; Gait, M.J. (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; and Lilley, D.M. and Dahlberg, J.E. (1992) Methods in Enzymology: DNA Structures Part A: DNA Synthesis and Physical Analysis, Academic Press. Each of these general texts is incorporated here by reference.

[00249] The publications discussed in the present invention are provided for disclosure only prior to the filing date of this application. Nothing in this invention should be construed as an admission that such publications constitute the prior art to the claims appended hereto.

[00250] The invention will now be further described by means of examples, which are intended to assist those skilled in the art in carrying out the invention and are not intended to limit the scope of the invention. Examples Example 1 - Effects on viral airway infection in early life and on allergic airway inflammation exacerbated by pollution. Detailed test design.

[00251] Figure 1 shows a schematic drawing of the model of viral airway infection in early life and allergic airway inflammation exacerbated by pollution. The test design is described in more detail below.

[00252] WT C57BL / 6 breeders were fed a control or low-fiber diet, starting 3 weeks before gestation. The offspring of these breeders were fed the corresponding diet of their mothers throughout the experiment, i.e., from postnatal day (PND) 0 to PND66. Petition 870250104625, dated 11 / 14 / 2025, pp. 68 / 117 59 / 76

[00253] In PND5, litters of animals fed a low-fiber diet were randomly assigned to different experimental groups (n = 14 to 16 / group). Mice were fed once daily with different combinations of nutritional ingredients (6HMOs; B. infantis LGM11588; B. infantis LGM11588+6HMOs) via intragastric (ig) gavage of 50 μL of ingredients in a saline solution ending in PND20. Control groups were fed saline only.

[00254] In PND10, all animals (n=13 to 16 / group) were infected intranasally (in) with 10 PFU of PVM (PVM, J3666) in a total volume of 40 μl in a saline solution (20 μl / nostril) to induce bronchiolitis. The virus-containing solution was delivered as droplets into the nostrils using P20 pipettes. Isoflurane-anesthetized mice were kept in a supine position to ensure proper inhalation of the solution.

[00255] The animals (n=7 to 8 / group) were sacrificed at PND20 (at the peak of bronchiolitis immunopathology) to measure virus-induced lung inflammation and associated pathology.

[00256] Starting at PND42, animals that recovered from PVM infection (n=7 to 8 / group) were sensitized in with cockroach allergen extracts (CRE, 1 mg / application) in combination with PM2.5 particulate matter (10 mg) once a week ending at PND63 (i.e., at PND42, PND49, PND56, PND63) to induce pollution-enhanced allergic airway inflammation.

[00257] Animals were sacrificed at PND20 (N=7 to 8 / group, at the peak of bronchiolitis immunopathology) to test the impact of nutritional interventions to promote protective immunity and at PND66 (N=7 to 8 / group) to assess susceptibility to pollution-induced allergic airway inflammation following viral infection. Petition 870250104625, dated 11 / 14 / 2025, pp. 69 / 117 60 / 76 of the airways. Probiotic dose

[00258] 106 CFU / day. HMO dose

[00259] A concentration of 4 mg / day and an application of a mixture of 6 HMOs (2FL / DFL, LNT, 3SL, 6SL, 3FL) were selected based on the most recent recommendations for HMOs in infant formulas (Stage 1: 1.8 to 2 g / l / day in the first 6 months).

[00260] The calculations were based on 1-week-old infants consuming 500 ml of breast milk / day and 10-day-old mouse pups consuming up to 2 ml of milk / day (source: Contemporary Topics in Laboratory Animal Science / American Association for Laboratory Animal Science 43(3):50 to 53).

[00261] The ratio between the ingredients of HMO is inspired by the composition of breast milk: ingredient 2FL / DFL 53%; ingredient LNT 19%; ingredient 6SL 8%, ingredient 3SL 6.2%; ingredient 3FL 13.8%.

[00262] In some experiments, a concentration of 4 mg / day and an application of a blend of 5 HMOs (2FL, DFL, LNT, 3SL, 6SL) were selected based on the most recent recommendations for HMOs in infant formulas (Stage 1: 1.8 to 2 g / l / day in the first 6 months). Ratios used for the 5HMO blend: 2FL / DFL ingredient 65.70%; LNT ingredient 23.40%; 6SL ingredient 9%; 3SL ingredient 2%. Low-fiber diet

[00263] WT C57BL / 6 mice efficiently eliminate the PVM virus. Such moderate infections are not associated with altered lung tissue remodeling that, in infants, predisposes to allergic airway inflammation later in life. To increase susceptibility to PVM infection and the associated risk of Petition 870250104625, dated 11 / 14 / 2025, pp. 70-117 61 / 76 allergic airway inflammation in adulthood, mothers and their corresponding offspring were fed a low-fiber diet throughout the experiment (susceptible groups; Trompette, Nat. Med, 2014). Animals fed a normal-fiber diet were used as protected controls (protected group). Statistical analysis

[00264] Statistical significance was determined using a two-way non-parametric ANOVA followed by the Bonferroni post-hoc test. Results were considered significant at P < 0.05. *P < 0.05; ** P < 0.01; *** P < 0.001. All statistical analyses were performed using Prism GraphPad software. Results PVM infection model

[00265] Mouse Pneumonia Virus (MPV) is related to the human respiratory syncytial virus (RSV) pathogen, which affects >90% of children by two years of age. MPV has been used to study respiratory virus replication and the resulting inflammatory response as a component of a natural host-pathogen relationship. Thus, MPV infections in mice reproduce many of the clinical and pathological features of the more severe forms of RSV infections in infants, which, if not adequately controlled, will have lasting consequences on lung function and predispose to the development of airway allergic responses later in life (Dyer KD, Viruses, 2012). The highly pathogenic MPV strain J3666 was selected for these studies to conform to the human pathophysiology of RSV infections in infants.

[00266] Severe bronchiolitis in early life is associated with mucus hypersecretion and desquamation of airway epithelial cells. Petition 870250104625, dated 11 / 14 / 2025, pp. 71 / 117 62 / 76 airways. Dead epithelial cells, along with a viscous exudate, can form dense plugs in the bronchioalveolar lumen that impede breathing. Controlled mucus secretion and epithelial cell death are beneficial defense mechanisms that limit viral spread. These responses need to be tightly regulated after virus clearance to prevent chronicity and pathological tissue remodeling.

[00267] The pathological features of a severe viral lower respiratory infection include airway epithelial cell shedding (AEC), mucus hypersecretion, and airway smooth muscle remodeling (ASM). AEC shedding is a feature of viral bronchiolitis and is associated with disease severity and viral load.

[00268] AEC desquamation was quantified by measuring the length of the desquamated airway epithelium and expressing this as a percentage of the airway basement membrane length in at least five airways per mouse. Mucus hypersecretion and pathological lung tissue remodeling as other features of severe bronchiolitis were assessed by quantifying Muc5ac-positive AECs, and ASM remodeling was assessed by airway area / circumference, respectively (Lynch JP, Jem 2018).

[00269] Early life nutritional intervention with a symbiotic (B. infantis + 6HMOs) resulted in a significant reduction in infection-mediated airway epithelial cell shedding (AEC) (Figure 2A), mucus secretion (Figure 2B), and pathological tissue remodeling (Figure 2C) compared to placebo-treated controls. Surprisingly, the symbiotic intervention showed superior efficacy over prebiotic (6HMO) or probiotic (B. infantis) interventions alone in reducing the Petition 870250104625, dated 11 / 14 / 2025, pp. 72 / 117 63 / 76 AEC desquamation mediated by infection, in mucus secretion and in pathological airway remodeling.

[00270] To assess whether early-life nutritional supplementation with the synbiotic, in addition to eliciting an effective antiviral immune response, results in controlled resolution of pulmonary inflammation after viral clearance, the number of neutrophils and / or eosinophils in the airways of mice infected with PVM was evaluated by flow cytometry. Importantly, supplementation with the synbiotic resulted in controlled resolution of pulmonary inflammation after virus clearance, as assessed by significantly reduced numbers of granulocytes (neutrophils and eosinophils) in the airways in response to PVM infection.

[00271] Early life nutritional intervention with a second symbiotic (B. infantis + 5HMOs) resulted in a significant upregulation of the antiviral cytokine IFN-λ 5 days post-infection (peak viral infection, Figure 5A), which was associated with a significant reduction in granulocytic cell infiltrates in inflamed lungs, as quantified by the number of pulmonary neutrophils (Figure 5B) and the number of pulmonary eosinophils (Figure 5C), suggesting that early life intervention with the symbiotic (B. infantis + 5HMOs) reduces severe virus-induced pulmonary inflammation. These data indicate that early life supplementation with the symbiotic controls effective antiviral immune responses and promotes rapid resolution of pulmonary inflammation and, therefore, recovery from respiratory infection. Model of allergic airway inflammation exacerbated by pollution.

[00272] Severe RSV infection early in life represents a significant risk factor for developing allergic airway disease later in life. Outdoor air pollution is a major Petition 870250104625, dated 11 / 14 / 2025, pp. 73-117 64 / 76 a global health problem. Exposure to particulate matter (PM) has been associated with the exacerbation of several respiratory diseases, including allergic asthma. To mimic such globally relevant conditions, animals recovered from severe PVM infection were sensitized with cockroach allergens in the presence of PM2.5 pollutant to induce allergic airway inflammation. This experimental approach allows testing whether nutritional intervention early in life (window of opportunity) not only alters susceptibility to viral bronchiolitis but may also have sustained immunological benefits into adulthood.

[00273] Early-life viral respiratory infections represent a potential tipping point in the balance between long-term respiratory health and chronic airway diseases, such as airway allergies. The present study shows that early-life nutritional symbiotic intervention not only reduced the severity of viral airway infection but also promoted a sustained immune benefit into adulthood, as assessed by reduced susceptibility to pollution-induced allergic airway inflammation.

[00274] This is exemplified by reduced numbers of pulmonary ILC2 (Figure 3A) and eosinophils (Figure 3B), as assessed by flow cytometry. Attenuated pulmonary inflammation was further associated with a reduced mucus score (Figure 4A) and improved tissue remodeling (Figure 4B). Surprisingly, and consistent with reduced susceptibility to airway viral infection (see Figure 2), the symbiotic intervention (B. infantis + 6HMOs) showed superior efficacy to prebiotic (6HMO) or probiotic (B. infantis) interventions alone in reducing pollution-intensified allergic airway inflammation in adulthood. Petition 870250104625, dated 11 / 14 / 2025, pp. 74 / 117 65 / 76 Conclusions

[00275] Using a neonatal mouse model of PVM-induced bronchiolitis and early-life nutritional interventions, symbiotic intervention (B. infantis in combination with a mixture of human milk oligosaccharides (5HMO or 6HMO)) was shown to provide protection against virus-induced bronchiolitis. Importantly, symbiotic intervention (B. infantis in combination with a mixture of human milk oligosaccharides (6HMO)) was shown to provide superior efficacy compared to 6HMOs alone or B. infantis alone in providing protection against virus-induced bronchiolitis. Specifically, symbiotic interventions resulted in rapid resolution of virus-induced lung inflammation and adequate lung tissue remodeling after virus clearance.

[00276] With the initial host response to respiratory viruses representing a potential tipping point in the balance between long-term respiratory health and chronic airway disease, these findings indicate that early-life nutritional intervention with these symbiotics (B. infantis + 6HMOs or B. infantis + 5HMOs) may represent a preventive strategy to combat severe bronchiolitis in infants and the associated risk of developing allergic airway disease in school-age children. Indeed, early-life nutritional symbiotic intervention not only reduced the severity of viral airway infection but also promoted a sustained immunological benefit into adulthood, as assessed by reduced susceptibility to allergic airway inflammation. In particular, these results provide strong evidence that early-life nutritional symbiotic intervention attenuates the pathological airway remodeling known as Petition 870250104625, dated 11 / 14 / 2025, pp. 75 / 117 66 / 76 increases the risk of chronic inflammatory diseases, such as asthma or COPD, later in life. Example 2 - Ex vivo fecal fermentation study Test design

[00277] This study was conducted with Cryptobiotix SA, using its proprietary ex vivo human gastrointestinal tract replica model and colonic microbiota incubations, as described in Van den Abbeele et al. Frontiers Microbiol. 2023.

[00278] Two arms were used in the study. These consisted of: 1. A blend of 7 HMOs: 2FL, 3FL, DFL, LNT, LNnT, 3SL, 6SL 2. 7 HMOs (2FL, 3FL, DFL, LNT, LNnT, 3SL, 6SL) + Children's B. LMG1188

[00279] Each arm consisted of six bioreactors (n = 6) inoculated with fecal microbiota from, respectively, 6 individual donors. The donors were 3-month-old (± 3 weeks) infants fed exclusively on HMO / probiotic-free formulas. Exclusion criteria were antibiotic use within 30 days prior to sample delivery for the study and previous NEC or gastrointestinal tract surgery. This resulted in the enrollment of 6 specific test subjects with a mean age of 3.1 (± 0.5) months. Intestinal absorption and colonic incubation conditions were then conducted (see Van den Abbeele et al. Frontiers Microbiol. 2023).

[00280] A blend of 7 HMOs was added to a final concentration of 2.66 g / l. The g / L composition of individual HMOs is described in the table below. HMO Quantity (g / l) 2FL 1.00 Petition 870250104625, dated 11 / 14 / 2025, pp. 76 / 117 67 / 76 3FL 0.38 DFL 0.14 3SL 0.10 6SL 0.18 LNT 0.35 LNnT 0.50 Total 2.66

[00281] B. infantis LMG11588 was dosed at a concentration of 5 x 107 CFU / ml.

[00282] Colon incubations were performed for 24 hours, with sampling at 0 and 24 hours for: • SCFA levels by HPLC • 16S rRNA community profile of the microbiome Results

[00283] Bifidobacterium breve levels were quantified in liquid after 24 h of incubation, as described in Van den Abbeele et al., 2023 (doi: 10.3389 / fmicb.2023.1131662). A 7-HMO blend was present as the sole carbon source in both conditions. The average of 6 donors is plotted. The bar on the left denotes the sum of B. breve levels when only a 7-HMO blend is present and the sum of B. breve levels when only B. infantis LMG 11588 at 5 x 107 CFU / ml is present (additive levels). The bar on the right denotes the B. breve levels when the same active ingredients are present together (conjunctive levels). The output when no active ingredient is subtracted from each individual condition (subtraction blank). The interaction between 7-HMO and B. infantis LMG 11588 when present together results in higher levels of B. breve than expected from the summed levels when only a blend of 7-HMO and only B. infantis LMG 11588 are present at 5 x 107. Petition 870250104625, dated 11 / 14 / 2025, pp. 77 / 117 68 / 76 CFU / ml are present (Figure 6). Therefore, the data show synergy between 7-HMOs in combination with B. infantis in establishing B. breve within fecal fermentation cultures. Conclusions

[00284] Using a fecal fermentation study, synergy was demonstrated between 7-HMOs in combination with B. infantis in the establishment of B. breve.

[00285] Along with B. infantis, Bifidobacterium breve is dominant in the stools of breastfed newborns and has a large body of evidence of immune modulation capacity (Bozzi Cionci, N., et al., Nutrients, 2018, 10(11)). This evidence includes beneficial modulation of immune responses in the lung, including reduced airway hyperreactivity, activation of type 2 helper T cells, eosinophilia, and production of allergen-specific antibodies (Hougee, S., et al., Int Arch Allergy Immunol, 2010, 151(2): 107-117).

[00286] Thus, the synergistic effect shown here is linked to pulmonary immunity.

[00287] All publications mentioned in the descriptive report above are incorporated herein by reference. Various modifications and variations of the methods and system described in the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in relation to specific preferred embodiments, it should be understood that the invention as claimed is not intended to be unduly limited to those specific embodiments. In fact, various modifications of the described modes for carrying out the invention, which are obvious to those skilled in molecular biology or related fields, are intended to be within the scope of the following claims. Petition 870250104625, dated 11 / 14 / 2025, pp. 78 / 117 69 / 76

[00288] Several preferred features and embodiments of the present invention will now be described with reference to the following numbered paragraphs:

[00289] 1. A composition for use in the prevention and / or treatment of a viral infection in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL) and 3-sialyl-lactose (3SL) and, optionally, 3-fucosyl-lactose (3FL) and / or lacto-N-neotetraose (LNnT).

[00290] 2. A composition for use in promoting a long-term immune benefit in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL) and 3'-sialyllactose (3SL) and optionally 3-fucosyl-lactose (3FL) and / or lacto-N-tetraose (LNnT).

[00291] 3. A composition for use i) in the prevention and / or reduction of the risk of sensitization to allergens and / or ii) in the prevention and / or reduction of the risk of developing a respiratory condition in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL) and 3'-sialyl-lactose (3SL) and, optionally, 3'-fucosyl-lactose (3FL) and / or lacto-N-neotetraose (LNnT).

[00292] 4. A composition for use in the prevention and / or reduction of the risk of developing asthma in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL) and Petition 870250104625, dated 11 / 14 / 2025, pp. 79 / 117 70 / 76 3'-sialyllactose (3SL) and, optionally, 3-fucosyllactose (3FL) and / or lacto-N-neotetraose (LNnT).

[00293] 5. The composition for use in accordance with any of the preceding paragraphs, and the mixture of HMOs consists of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and 3-fucosyl-lactose (3FL).

[00294] 6. The composition for use in accordance with any of paragraphs 1 to 4, with the mixture of HMOs consisting of 2'-fucosillactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialillactose (6SL), 3'-sialyl-lactose (3SL) and lacto-N-neotetraose (LNnT).

[00295] 7. The composition for use in accordance with any of paragraphs 1 to 4, with the mixture of HMOs consisting of 2'-fucosillactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialillactose (6SL), 3'-sialyl-lactose (3SL), 3-fucosyl-lactose (3FL) and lacto-N-tetraose (LNnT).

[00296] 8. The composition for use in accordance with any of the preceding paragraphs, wherein Bifidobacterium longum subspecies infantis is Bifidobacterium longum subspecies infantis LMG 11588 or a strain with an Average Nucleotide Identity (ANI) of at least 99.9% with Bifidobacterium longum subspecies infantis LMG 11588.

[00297] 9. The composition for use in accordance with any of the preceding paragraphs, the composition additionally comprising Bifidobacterium animalis subspecies lactis.

[00298] 10. The composition for use in accordance with paragraph 9, wherein Bifidobacterium animalis subspecies lactis is Bifidobacterium animalis subspecies lactis CNCM I-3446 or a strain with an Average Nucleotide Identity (ANI) of at least 99.9% with Bifidobacterium animalis subspecies lactis CNCM I-3446.

[00299] 11. The composition for use according to any Petition 870250104625, dated 11 / 14 / 2025, pp. 80 / 117 71 / 76 of paragraphs 1 to 5 or 8 to 10, where the mixture of HMOs essentially consists of: i. 31% by weight to 82% by weight of 2FL, preferably 41% by weight to 70% by weight; ii. 10% by weight to 27% by weight of LNT, preferably 14% by weight to 23% by weight; iii. 4% by weight to 11% by weight of DFL, preferably 6% by weight to 10% by weight; and iv. 9% by weight to 34% by weight of 6SL and 3SL combined, preferably 11% by weight to 29% by weight.

[00300] 12. The composition according to any of paragraphs 1 to 4, 6 or 8 to 10, wherein the mixture of HMOs consists essentially of: i. 16% by weight to 69% by weight of 2FL, preferably 22% by weight to 59% by weight; ii. 9% by weight to 24% by weight of LNT, preferably 12% by weight to 21% by weight; iii. 2% by weight to 10% by weight of DFL, preferably 3% by weight to 8% by weight; iv. 8% by weight to 26% by weight of 6SL and 3SL combined, preferably 11% by weight to 22% by weight; and v. 18% by weight to 50% by weight of 3FL, preferably 11% by weight to 43% by weight.

[00301] 13. The composition for use in accordance with any of paragraphs 1 to 5 or 8 to 10, wherein the mixture of HMOs consists essentially of: i. 34% by weight to 85% by weight of 2FL, preferably 40% by weight to 71% by weight; ii. 10% by weight to 40% by weight of LNT, preferably 12% by weight to 26% by weight; Petition 870250104625, dated 11 / 14 / 2025, pp. 81 / 117 72 / 76 iii. 4% by weight to 14% by weight of DFL, preferably 5% by weight to 10% by weight; iv. 9% by weight to 31% by weight of 6SL and 3SL combined, preferably 10% by weight to 28% by weight; and v. 6% by weight to 30% by weight of LNnT, preferably 7% by weight to 22% by weight.

[00302] 14. The composition according to any of paragraphs 1 to 4, 6 or 8 to 10, wherein the mixture of HMOs consists essentially of: i. 20% by weight to 60% by weight of 2FL, preferably 22% by weight to 55% by weight; ii. 4% by weight to 30% by weight of LNT, preferably 6% by weight to 20% by weight; iii. 1% by weight to 12% by weight of DFL, preferably 2% by weight to 8% by weight; iv. 7% by weight to 23% by weight of 6SL and 3SL combined, preferably 8% by weight to 22% by weight; v. 10% by weight to 50% by weight of 3FL, preferably 13% by weight to 46% by weight; and vi. 3% by weight to 25% by weight of LNnT, preferably 5% by weight to 20% by weight.

[00303] 15. The composition for use in accordance with any of the preceding paragraphs, wherein the composition is a nutritional composition selected from an infant formula, an infant starter formula, a follow-on or transitional formula, an infant food, an infant cereal composition, a growing-up milk, a fortifier, such as a human milk fortifier, or a supplement.

[00304] 16. The composition for use in accordance with any of the preceding paragraphs, wherein the individual is a baby, a Petition 870250104625, dated 11 / 14 / 2025, pp. 82 / 117 73 / 76 toddler or child.

[00305] 17. The composition for use in accordance with any of paragraphs 1 or 5 to 16, wherein the composition is intended for use in the prevention and / or treatment of a viral respiratory tract infection.

[00306] 18. The composition for use in accordance with any of paragraphs 1 or 5 to 17, wherein the viral infection causes a disease selected from the group consisting of the common cold, influenza (flu), bronchitis, bronchiolitis and pneumonia.

[00307] 19. The composition for use in accordance with paragraph 18, where the disease is bronchiolitis or pneumonia, preferably bronchiolitis.

[00308] 20. The composition is for use in accordance with any of paragraphs 1 or 5 to 18, wherein the composition is intended for use in reducing the risk of developing viral infection and / or in reducing the symptoms associated with viral infection.

[00309] 21. The composition for use in accordance with paragraph 20, wherein the symptoms associated with viral infection are selected from the group consisting of lung irritation, lung congestion, excessive mucus production, fever, cough, wheezing, shortness of breath, abdominal cramps, diarrhea and vomiting.

[00310] 22. The composition for use in accordance with any of paragraphs 1 or 5 to 21, wherein the viral infection is caused by a virus selected from the group consisting of respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza virus, such as influenza A virus (IVA) and / or influenza B virus (IVB), rhinovirus (RV), adenovirus (ADV), metapneumovirus (MPV), bocavirus (BoV), coronavirus (CoV), myxovirus, herpesvirus, enterovirus (EV) and paracovirus (PeV), or any combination thereof.

[00311] 23. The composition for use according to any Petition 870250104625, dated 11 / 14 / 2025, pp. 83 / 117 74 / 76 of paragraphs 1 or 5 to 22, wherein the viral infection is respiratory syncytial virus (RSV) or rhinovirus (RV) infection, preferably RSV infection.

[00312] 24. The composition for use in accordance with any of paragraphs 2 or 5 to 16, wherein the promotion of a long-term immune benefit in an individual comprises: i. to promote long-term respiratory health; ii. to prevent and / or reduce the risk of sensitization to allergens; and / or iii. to prevent and / or reduce the risk of developing a respiratory condition later in life.

[00313] 25. The composition for use in accordance with any of paragraphs 3, 5 to 16 or 24, wherein the respiratory condition is a chronic inflammatory disease of the respiratory tract or an allergic disease of the respiratory tract.

[00314] 26. The composition for use in accordance with paragraph 25, wherein the chronic inflammatory disease of the respiratory tract is asthma or chronic obstructive pulmonary disease (COPD).

[00315] 27. The composition for use in accordance with paragraph 25, wherein the allergic respiratory tract disease is recurrent wheezing or asthma, preferably allergic asthma.

[00316] 28. The composition for use in accordance with any of paragraphs 3, 5 to 16 or 24 to 27, wherein the composition is intended for use i) in the prevention and / or reduction of the risk of sensitization to allergens and / or ii) in the prevention and / or reduction of the risk of developing a respiratory condition in the individual later in life.

[00317] 29. The composition for use in accordance with any of paragraphs 4 to 16 or 24 to 27, the composition being intended for use in the prevention and / or reduction of the risk of developing asthma in the individual later in life. Petition 870250104625, dated 11 / 14 / 2025, pp. 84 / 117 75 / 76

[00318] 30. The composition for use in accordance with paragraph 28 or paragraph 29, which is later in life 12 months to 12 years after the end of treatment.

[00319] 31. A method for: i) to prevent and / or treat a viral infection in an individual; ii) to promote a long-term immune benefit in an individual; iii) to prevent and / or reduce the risk of sensitization to allergens in an individual; iv) to prevent and / or reduce the risk of developing a respiratory condition in an individual; and / or (v) to prevent asthma in an individual, wherein the method comprises administering to the individual a composition as defined in any of paragraphs 1 to 30.

[00320] 32. A composition comprising Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL), 3-fucosyl-lactose (3FL) and lacto-N-neotetraose (LNnT).

[00321] 33. The composition according to paragraph 32, wherein Bifidobacterium longum subspecies infantis is Bifidobacterium longum subspecies infantis LMG 11588 or a strain with an Average Nucleotide Identity (ANI) of at least 99.9% with Bifidobacterium longum subspecies infantis LMG 11588.

[00322] 34. The composition according to paragraph 32 or paragraph 33, the composition additionally comprising Bifidobacterium animalis subspecies lactis.

[00323] 35. The composition for use in accordance with paragraph 34, wherein Bifidobacterium animalis subspecies lactis is Bifidobacterium animalis subspecies lactis CNCM I-3446 or a strain Petition 870250104625, dated 11 / 14 / 2025, pp. 85 / 117 76 / 76 with an Average Nucleotide Identity (ANI) of at least 99.9% with Bifidobacterium animalis subspecies lactis CNCM I-3446.

[00324] 36. The composition according to any of paragraphs 32 to 36, wherein the composition is a nutritional composition selected from an infant formula, an infant starter formula, a follow-on or transitional formula, an infant food, an infant cereal composition, a growing-up milk, a fortifier, such as a human milk fortifier or a supplement. Petition 870250104625, dated 11 / 14 / 2025, pp. 86 / 117

Claims

1 / 6 CLAIMS 1. Use of Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL), characterized in that it is for the preparation of a medicament and / or composition comprising the same, for the prevention and / or treatment of a viral infection in an individual.

2. Use of Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and 3-fucosyl-lactose (3FL), and lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL), characterized in that it is for the preparation of a medicament and / or composition comprising the same, for (i) prevention and / or reduction of the risk of sensitization to allergens in the respiratory tract and / or (ii) prevention and / or reduction of the risk of developing a respiratory condition in an individual, wherein the respiratory condition is a chronic inflammatory disease of the respiratory tract or an allergic disease of the respiratory tract.

3. Use of Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL), characterized in that it is for the preparation of a medicament and / or composition comprising the same, for the prevention and / or reduction of the risk of developing asthma in an individual.

4. Use, according to any of claims 1 to Petition 870250104625, dated 11 / 14 / 2025, page 93 / 117 2 / 6 3, characterized in that the HMO mixture consists of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and lacto-N-neotetraose (LNnT).

5. Use, according to any one of claims 1 to 4, characterized in that the HMO mixture consists essentially of: i. 34% by weight to 85% by weight of 2FL, or 40% by weight to 71% by weight; ii. 10% by weight to 40% by weight of LNT, or 12% by weight to 26% by weight; iii. 4% by weight to 14% by weight of DFL, or 5% by weight to 10% by weight; iv. 9% by weight to 31% by weight of 6SL and 3SL combined, or 10% by weight to 28% by weight; and v. 6% by weight to 30% by weight of LNnT, or 7% by weight to 22% by weight.

6. Use, according to any one of claims 1 to 3, characterized in that the mixture of HMOs consists of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and 3-fucosyl-lactose (3FL) and lacto-N-neotetraose (LNnT).

7. Use, according to any one of claims 1 to 3 or 6, characterized in that the HMO mixture consists essentially of: i. 20% by weight to 60% by weight of 2FL, or 22% by weight to 55% by weight; ii. 4% by weight to 30% by weight of LNT, or 6% by weight to 20% by weight; iii. 1% by weight to 12% by weight of DFL, or 2% by weight to 8% by weight; iv. 7% by weight to 23% by weight of 6SL and 3SL combined, or 8% by weight to 22% by weight; v. 10% by weight to 50% by weight of 3FL, or 13% by weight to 46% by weight; and vi. 3% by weight to 25% by weight of LNnT, or 5% by weight to 20% by weight.

8. Use, according to any of claims 1 to 7, characterized in that the Bifidobacterium longum subspecies infantis is Bifidobacterium longum subspecies infantis LMG 11588 or a strain with an Average Nucleotide Identity (ANI) of at least 99.9% with Bifidobacterium longum subspecies infantis LMG 11588.

9. Use, according to any one of claims 1 to 8, characterized in that the composition is a nutritional composition selected from an infant formula, an infant starter formula, a transition or follow-up formula, an infant food, an infant cereal composition, a growing-up milk, a fortifier, such as a human milk fortifier, or a supplement.

10. Use, according to any one of claims 1 to 9, characterized in that the individual is an infant, a toddler or a child.

11. Use, according to any of claims 1 or 4 to 10, characterized in that the composition is for reducing the risk of developing viral infection and / or reducing the symptoms associated with viral infection.

12. Use, according to any of claims 1 or 4 to 11, characterized in that the viral infection is caused by a virus selected from the group consisting of respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza virus, such as influenza A virus (IVA) and / or influenza B virus (IVB), rhinovirus (RV), adenovirus (ADV), metapneumovirus (MPV), bocavirus (BoV), coronavirus (CoV), myxovirus, herpesvirus, enterovirus (EV) and paracovirus (PeV), or any combination thereof, or wherein the viral infection is caused by RSV.

13. Use, according to any one of claims 2 or 4 to 10, characterized in that the chronic inflammatory disease of the respiratory tract is asthma or chronic obstructive pulmonary disease (COPD).

14. Use, according to any one of claims 2 or 4 to 10, characterized by the fact that the allergic respiratory tract disease is recurrent wheezing or asthma.

15. Use of Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL), characterized in that it is for the preparation of a medicament and / or composition comprising the same, for: (i) preventing and / or treating a viral infection in an individual; (ii) preventing and / or reducing the risk of sensitization to allergens in an individual; (iii) preventing and / or reducing the risk of developing a respiratory condition in an individual; and / or (iv) preventing asthma in an individual.

16. Composition, characterized in that it comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL), 3-fucosyl-lactose (3FL) and lacto-N-neotetraose (LNnT).

17. Composition, characterized in that it comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyllactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyllactose (3SL) and lacto-N-neotetraose (LNnT).

18. Infant formula, infant starter formula, transition or follow-up formula, infant food, infant cereal composition, growing-up milk, fortifier and / or a supplement, characterized in that it comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-Ntetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and lacto-Nneotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL).

19. Invention, characterized by the fact that it is in any of its embodiments or in any applicable category of claim, for example, product or process or use, or any other type of claim encompassed by the matter initially described, disclosed or illustrated in the patent application, for example: Composition for use in the prevention and / or treatment of a viral infection in an individual, wherein the composition is Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-Ntetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and lacto-Nneotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL);and / or Composition for use (i) in the prevention and / or reduction of the risk of sensitization to allergens in the respiratory tract and / or (ii) in the prevention and / or reduction of the risk of developing a condition Petition 870250104625, dated 11 / 14 / 2025, page. 97 / 117 6 / 6 respiratory in an individual, the composition comprising Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosyl-lactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialyl-lactose (3SL) and 3-fucosyllactose (3FL), and lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL), and the respiratory condition being a chronic inflammatory disease of the respiratory tract or an allergic disease of the respiratory tract;and / or Composition for use in the prevention and / or reduction of the risk of developing asthma in an individual, wherein the composition comprises Bifidobacterium longum subspecies infantis and a mixture of HMOs consisting of 2'-fucosyl-lactose (2FL), difucosillactose (DFL), lacto-N-tetraose (LNT), 6'-sialyl-lactose (6SL), 3'-sialillactose (3SL) and lacto-N-neotetraose (LNnT) and, optionally, 3-fucosyl-lactose (3FL); and / or Method for: (i) preventing and / or treating a viral infection in an individual; (ii) preventing and / or reducing the risk of sensitization to allergens in an individual; (iii) preventing and / or reducing the risk of developing a respiratory condition in an individual; and / or (iv) preventing asthma in an individual, wherein the method comprises administering to the individual a composition as defined in any of the preceding claims. Petition 870250104625, dated 11 / 14 / 2025, pp. 98 / 117;